<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00386334</url>
  </required_header>
  <id_info>
    <org_study_id>190-904</org_study_id>
    <nct_id>NCT00386334</nct_id>
  </id_info>
  <brief_title>A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly With Primary Chronic Insomnia</brief_title>
  <official_title>A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly Subjects With Primary Chronic Insomnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the long-term safety and efficacy of eszopiclone administered for 12 weeks in
      elderly subjects with primary chronic insomnia.Administration of eszopiclone 2 mg daily at
      bedtime for 12 weeks in elderly subjects with a diagnosis of primary chronic insomnia will be
      safe and well tolerated, improve subjective sleep measures, improve measures of Quality of
      Life and next day insomnia symptoms, and have no significant withdrawal central nervous
      system adverse events or rebound insomnia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double-blind, randomized, placebo controlled, parallel group study of eszopiclone in
      elderly subjects with primary chronic insomnia. The study will involve up to 9 visits and
      subject participation will be approximately 18 weeks. This study was previously posted by
      Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and
      in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in Subject-Reported Total Sleep Time (TST) Averaged Over the 12 Week Double Blind Study Period.</measure>
    <time_frame>Baseline (week 0), Day 1 (post first dose)-12 weeks</time_frame>
    <description>The difference between the total sleep time at baseline and the average total sleep time over the double blind period(average of post-dose values from weeks 3,6,9,12) reported by the participant. The change is calculated as the average over the double blind period minus the baseline value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Subject-reported Total Sleep Time at Various Study Time Points.</measure>
    <time_frame>Weeks 0, 3, 6, 9, 12, 14, 16</time_frame>
    <description>The difference between the total sleep time at baseline and at different time points in the double-blind period (weeks 3,6,9,12), the single-blind follow-up (week 14) and the non-drug treatment follow-up (week 16). The change is calculated as the time point value minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Subject-reported Total Sleep Time in Minutes at Various Study Time Points.</measure>
    <time_frame>Weeks 0, 3, 6, 9, 12, 14, 16</time_frame>
    <description>The mean total minutes asleep each night at different time points: baseline(week 0), double-blind phase(weeks 3,6,9,12), the single-blind follow-up(week 14),the non-drug treatment follow-up(week 16), and the double-blind average(average of weeks 3,6,9,12 values).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Subject-reported Sleep Latency (SL) Averaged Over the 12 Week Double Blind Period.</measure>
    <time_frame>Baseline (week 0), Day 1 (post first dose) - Week12</time_frame>
    <description>Sleep latency answers how long it takes to fall asleep. The difference between the sleep latency at baseline and the average sleep latency over the double blind period(average of post-dose values from weeks 3,6,9,12) reported by the participant. The change is calculated as the average over the double blind period minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Subject-reported Sleep Latency at Various Study Time Points</measure>
    <time_frame>Baseline (week 0), Weeks 3,6,9,12,14,16</time_frame>
    <description>Sleep latency answers the question: How long did it take you to fall asleep last night? The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Subject-reported Sleep Latency Reported at Various Study Time Points.</measure>
    <time_frame>Weeks 0,3,6,9,12,14,16</time_frame>
    <description>Sleep latency answers the question: How long did it take you to fall asleep last night? Mean values are reported at baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the entire double-blind phase(average of weeks 3,6,9,12 values).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Subject-reported Wake Time After Sleep Onset (WASO) Averaged Over the 12 Week Double-blind Study Period.</measure>
    <time_frame>Baseline (week 0), Day 1 (post first dose) -week 12</time_frame>
    <description>Wake time after sleep onset (WASO) is the time spent awake from sleep onset to final awakening. The difference between WASO at baseline and the average WASO over the double blind period(average of post-dose values from weeks 3,6,9,12). The change is calculated as the average over the double blind period minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Subject-reported Wake Time After Sleep Onset (WASO) at Various Study Time Points.</measure>
    <time_frame>Baseline (week 0), weeks 3,6,9,12,14,16</time_frame>
    <description>Wake time after sleep onset is the time spent awake from sleep onset to final awakening. The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Subject-reported Wake Time After Sleep Onset (WASO) at Various Study Time Points</measure>
    <time_frame>Weeks 0,3,6,9,12,14,16</time_frame>
    <description>Wake time after sleep onset is the time spent awake from sleep onset to final awakening. Mean values are reported at baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the entire double-blind phase(average of weeks 3,6,9,12 values).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Subject-reported Number of Awakenings Averaged Over the 12 Week Double Blind Study Period.</measure>
    <time_frame>Baseline (week 0), Day 1 (post first dose) - Week12</time_frame>
    <description>The number of awakenings is the number of times a subject wakes up between the initial onset of sleep and the final awakening. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of Subject-reported Awakenings at Various Study Time Points.</measure>
    <time_frame>Baseline (week 0), Weeks 3,6,9,12,14,16</time_frame>
    <description>The number of awakenings refers to the number of times a subject wakes up between the initial onset of sleep and the final awakening. The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Awakenings (Subject-reported) at Various Study Time Points</measure>
    <time_frame>Weeks 0,3,6,9,12,14,16</time_frame>
    <description>Number of awakenings is number of times a subject wakes up between initial onset of sleep and final awakening. Mean values are reported at baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the double-blind phase(average of weeks 3,6,9,12 values).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Subject-reported Quality of Sleep Averaged Over the 12 Week Double Blind Study Period</measure>
    <time_frame>Baseline (week 0), Day 1 (post first dose) - Week12</time_frame>
    <description>Quality of sleep was rated by participants on a scale of 0-10, with higher scores representing better quality sleep. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Subject-reported Quality of Sleep at Various Study Time Points.</measure>
    <time_frame>Baseline (week 0), Weeks 3,6,9,12,14,16</time_frame>
    <description>Sleep quality was rated by subjects on a scale from 0-10, with higher scores representing better quality sleep. The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Ratings of Subject-reported Quality of Sleep at Various Study Time Points</measure>
    <time_frame>weeks 0,3,6,9,12,14,16</time_frame>
    <description>Quality of sleep was rated by participants on a scale of 0-10, with higher scores representing better quality sleep. Mean values are reported at baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the double-blind phase(average of weeks 3,6,9,12 values).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Subject-Reported Depth of Sleep for the Average Reported During the Double-blind Period.</measure>
    <time_frame>Baseline (week 0), Day 1 (post first dose) - week 12</time_frame>
    <description>Depth of sleep was reported by study participants using a scale from 0-10, with higher scores representing better sleep. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Subject-reported Depth of Sleep at Various Study Time Points</measure>
    <time_frame>Baseline (week 0), Weeks 3,6,9,12,14,16</time_frame>
    <description>Depth of sleep was reported by study participants using a scale from 0-10, with higher scores representing better sleep. The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Subject-reported Depth of Sleep at Various Study Time Points</measure>
    <time_frame>weeks 0,3,6,9,12,14,16</time_frame>
    <description>Depth of sleep was reported by study participants using a scale from 0-10, with higher scores representing better sleep. Mean values reported: baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the double-blind phase(average of weeks 3,6,9,12 values).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Subject-reported Daytime Alertness Averaged Over the 12 Week Double Blind Study Period</measure>
    <time_frame>Baseline (week 0), Day 1 (post first dose) - week 12</time_frame>
    <description>Daytime alertness was rated by study participants on a scale of 0-10, with higher scores representing better alertness. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Subject-reported Daytime Alertness at Various Study Time Points</measure>
    <time_frame>Baseline (week 0), Weeks 3,6,9,12,14,16</time_frame>
    <description>Daytime alertness was rated by study participants on a scale of 0-10, with higher scores representing better alertness. The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Subject-reported Daytime Alertness at Various Study Time Points.</measure>
    <time_frame>Weeks 0,3,6,9,12,14,16</time_frame>
    <description>Daytime alertness was rated by study participants on a scale of 0-10, with higher scores representing better alertness. Mean values reported: baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the double-blind phase(average of weeks 3,6,9,12 values).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Subject-Reported Ability to Function Averaged Over the 12 Week Double Blind Period</measure>
    <time_frame>Baseline (week 0), Day 1 (post first dose) - week 12</time_frame>
    <description>Ability to function was rated by study participants on a scale of 0-10, with higher scores representing better ability to function. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Subject-reported Ability to Function at Various Study Time Points</measure>
    <time_frame>Baseline (week 0), Weeks 3,6,9,12,14,16</time_frame>
    <description>Ability to function was rated by study participants on a scale of 0-10, with higher scores representing better ability to function. The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Subject-reported Ability to Function at Various Study Time Points</measure>
    <time_frame>Weeks 0,3,6,9,12,14,16</time_frame>
    <description>Ability to function was rated by study participants on a scale of 0-10, with higher scores representing better ability to function. Mean values reported: baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16) &amp; average for double-blind phase(average of weeks 3,6,9,12 values).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Subject-reported Ability to Concentrate Averaged Over the 12 Week Double Blind Study Period.</measure>
    <time_frame>Baseliine (week 0), Day 1 (post first dose) - week 12</time_frame>
    <description>Ability to concentrate was rated by study participants on a scale of 0-10, with higher scores representing better concentration. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Subject-reported Ability to Concentrate at Various Study Time Points.</measure>
    <time_frame>Baseline (week 0), Weeks 3,6,9,12,14,16</time_frame>
    <description>Ability to concentrate was rated by study participants on a scale of 0-10, with higher scores representing better concentration. The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Subject-reported Ability to Concentrate at Various Study Time Points</measure>
    <time_frame>Weeks 0,3,6,9,12,14,16</time_frame>
    <description>Ability to concentrate was rated by study participants on a scale of 0-10, with higher scores representing better concentration. Mean values reported: baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16) &amp; average for the double-blind phase(average of weeks 3,6,9,12 values).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Subject-reported Physical Well-Being Averaged Over the 12 Week Double Blind Study Period</measure>
    <time_frame>Baseline (week 0), Day 1 (post first dose) - week 12</time_frame>
    <description>Physical well-being was rated by study participants on a scale of 0-10, with higher scores representing better well-being. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Subject-reported Physical Well-being at Various Study Time Points.</measure>
    <time_frame>Baseline (week 0), Weeks 3,6,9,12,14,16</time_frame>
    <description>Physical well-being was rated by study participants on a scale of 0-10, with higher scores representing better well-being. The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Subject-reported Physical Well-Being at Various Study Time Points</measure>
    <time_frame>Weeks 0,3,6,9,12,14,16</time_frame>
    <description>Physical well-being was rated by study participants on a scale of 0-10, with higher scores representing better well-being. Mean values reported: baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), &amp; average for double-blind phase(average of weeks 3,6,9,12 values).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Subject-Reported Counts of Number of Naps Per Week Averaged Over the 12 Week Double Blind Study Period</measure>
    <time_frame>Baseline (week 0), Day 1 (post first dose)- week 12</time_frame>
    <description>Change from baseline in the number of naps per week for subjects who napped during the baseline period. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline In Subject-Reported Counts of Number of Naps Per Week at Various Study Time Points</measure>
    <time_frame>Baseline (week 0), Weeks 3,6,9,12,14,16</time_frame>
    <description>Change from baseline in the number of naps per week for subjects who napped during the baseline period. The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Subject-Reported Number of Naps Each Week at Various Study Time Points.</measure>
    <time_frame>Weeks 0,3,6,9,12,14,16</time_frame>
    <description>The mean number of naps per week for subjects who napped during the baseline period. Mean values are reported at baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the double-blind phase(average of weeks 3,6,9,12 values).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Subject-Reported Total Nap Time Per Week Averaged Over the 12 Week Double Blind Study Period</measure>
    <time_frame>Baseline (week 0), Day 1 (post first dose) - week 12</time_frame>
    <description>Change from baseline in the total time (minutes) spent napping per week for subjects who napped during the baseline period. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Subject-Reported Total Nap Time Per Week at Various Study Time Points.</measure>
    <time_frame>Baseline (week 0), Weeks 3,6,9,12,14,16</time_frame>
    <description>Change from baseline in the total time (minutes) spent napping per week for subjects who napped during the baseline period. The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Subject-Reported Total Nap Time at Various Study Time Points</measure>
    <time_frame>Weeks 0,3,6,9,12,14,16</time_frame>
    <description>The total time (minutes) spent napping per week for subjects who napped during the baseline period. Mean values are reported at baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the double-blind phase(average of weeks 3,6,9,12 values).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Subject-Reported Total Nap Time Per Week as a Percent of Total Asleep Time Averaged Over the 12 Week Double Blind Study Period</measure>
    <time_frame>Baseline (week 0), Day 1 (post first dose) - week 12</time_frame>
    <description>Change from baseline in the total time spent napping per week stated as a percentage of the total time asleep for subjects who napped during the baseline period. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Subject-Reported Total Nap Time Stated as a Percentage of the Total Asleep Time at Various Study Time Points</measure>
    <time_frame>Baseline (week 0), Weeks 3,6,9,12,14,16</time_frame>
    <description>Change from baseline in the total time spent napping per week stated as a percentage of the total time asleep for subjects who napped during the baseline period. The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Subject-Reported Total Nap Time Per Week Stated as a Percentage of the Total Asleep Time at Various Study Time Points</measure>
    <time_frame>Weeks 0,3,6,9,12,14,16</time_frame>
    <description>Total time spent napping per week stated as a percentage of total time asleep for subjects who napped during baseline period. Mean values reported: baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week14), non-drug treatment follow-up(week 16), &amp; average for double-blind phase(average of weeks 3,6,9,12 values).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Total Sleep Time Measured by Actigraphy Averaged Over the 12 Week Double Blind Study Period</measure>
    <time_frame>Baseline (week 0), Day 1 (post first dose) - week 12</time_frame>
    <description>Participants who wore an actigraph wrist monitor, which monitors rest and activity cycles are included; the resultant data had total sleep time calculated by a Central Reader. The change is calculated as the average over the double blind period (average of post-dose values from weeks 1,4,7,12) minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Total Sleep Time Measured by Actigraphy at Various Study Time Points</measure>
    <time_frame>Baseline (week 0), Weeks 1,4,7,12,13,15</time_frame>
    <description>Change from baseline in total sleep time for the subset population who wore an actigraph wrist monitor. The actigraph monitors rest and activity cycles; the resultant data had sleep parameters calculated by a Central Reader. The change is calculated as time point value minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Total Sleep Time Measured by Actigraphy at Various Study Time Points</measure>
    <time_frame>Weeks 0,1,4,7,12,13,15</time_frame>
    <description>Total sleep time for subset who wore actigraph wrist monitor which monitors rest and activity cycles, sleep parameters calculated by Central Reader. Mean values reported:baseline(week0), double-blind(weeks1,4,7,12), single-blind follow-up(week13), non-drug follow-up(week15) &amp; average for double-blind(average of weeks1,4,7,12 values).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Sleep Latency Measured Using Actigraphy Averaged Over the 12 Week Double Blind Study Period</measure>
    <time_frame>Baseline (week 0), Day 1 (post first dose) - week 12</time_frame>
    <description>Sleep latency is the time it takes to fall asleep. Participants who wore an actigraph wrist monitor to record rest and activity cycles are included; a Central Reader calculated sleep parameters. The change is calculated as the average over the double blind period (average of post-dose values from weeks 1,4,7,12) minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Sleep Latency Measured Using Actigraphy at Various Study Time Points</measure>
    <time_frame>Baseline (week 0), Weeks 1,4,7,12,13,15</time_frame>
    <description>Sleep latency is a measurement of the time it takes to fall asleep. Participants who wore an actigraph wrist monitor to record rest and activity cycles are included; a Central Reader calculated sleep parameters. The change is calculated as time point value minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Sleep Latency Values Measured Using Actigraphy at Various Study Time Points.</measure>
    <time_frame>Weeks 0,1,4,7,12,13,15</time_frame>
    <description>Sleep latency:measurement of time to fall asleep. Values are for subset who wore an actigraph wrist monitor which monitors rest and activity cycles; sleep parameters calculated by Central Reader.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Wake Time After Sleep Onset (WASO) Measured by Actigraphy Averaged Over the 12 Week Double Blind Study Period</measure>
    <time_frame>Baseline (week 0), Day 1 (post first dose) - week 12</time_frame>
    <description>Wake time after sleep onset is the time spent awake from sleep onset to final awakening. Change is calculated as average over double blind period (average of post-dose values from weeks 1,4,7,12) minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Wake Time After Sleep Onset Measured Using Actigraphy at Various Study Time Points</measure>
    <time_frame>Baseline (week 0), Weeks 1,4,7,12,13,15</time_frame>
    <description>Wake time after sleep onset is the time spent awake from sleep onset to final awakening. Participants who wore an actigraph wrist monitor to record rest and activity cycles are included; a Central Reader calculated sleep parameters. The change is calculated as time point value minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Values for Wake Time After Sleep Onset Measured Using Actigraphy at Various Study Time Points</measure>
    <time_frame>weeks 0,1,4,7,12,13,15</time_frame>
    <description>Wake time after sleep onset is time spent awake from sleep onset to final awakening. Mean values reported: baseline(week 0), double-blind phase(weeks 1,4,7,12), single-blind follow-up(week 13), non-drug treatment follow-up(week 15) &amp; average for double-blind phase(average of weeks 1,4,7,12 values).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Number of Awakenings Using Actigraphy Averaged Over the 12 Week Double Blind Study Period</measure>
    <time_frame>Baseline (week 0), Day 1 (post first dose) - week 12</time_frame>
    <description>Number of awakenings refers to the number of times a subject awakens between first sleep onset to final awakening. Change is calculated as average over double blind period (average of post-dose values from weeks 1,4,7,12) minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of Awakenings Measured Using Actigraphy at Various Study Time Points.</measure>
    <time_frame>Baseline (week 0), Weeks 1,4,7,12,13,15</time_frame>
    <description>Number of awakenings refers to the number of times a subject awakens between first sleep onset to final awakening. Participants who wore an actigraph wrist monitor to record rest and activity cycles are included; a Central Reader calculated sleep parameters. The change is calculated as time point value minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Awakenings Measured Using Actigraphy at Various Study Time Points</measure>
    <time_frame>Weeks 0,1,4,7,12,13,15</time_frame>
    <description>Number of awakenings refers to the number of times a subject awakens between first sleep onset to final awakening. Mean values are reported at baseline(week 0), double-blind phase(weeks 1,4,7,12), single-blind follow-up(week 13), non-drug treatment follow-up(week 15), and the average for the double-blind phase(average of weeks 1,4,7,12 values).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Number of Naps Per Week Measured Using Actigraphy Averaged Over the 12 Week Double Blind Study Period</measure>
    <time_frame>Baseline (week 0), Day 1 (post first dose) - week 12</time_frame>
    <description>Change from baseline in the number of naps per week for subjects who napped during the baseline period. Change is calculated as the average over the double blind period (average of post-dose values from weeks 1,4,7,12) minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of Naps Per Week Measured Using Actigraphy at Various Study Time Points</measure>
    <time_frame>Baseline (week 0), Weeks 1,4,7,12,13,15</time_frame>
    <description>Change from baseline in the number of naps per week for subjects who napped during the baseline period. Participants who wore an actigraph wrist monitor to record rest and activity cycles are included; a Central Reader calculated sleep parameters. The change is calculated as time point value minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Naps Per Week Measured Using Actigraphy at Various Study Time Points</measure>
    <time_frame>Week 0,1,4,7,12,13,15</time_frame>
    <description>The number of naps per week for subjects who napped during the baseline period. Mean values are reported at baseline(week 0), double-blind phase(weeks 1,4,7,12), single-blind follow-up(week 13), non-drug treatment follow-up(week 15), and the average for the double-blind phase(average of weeks 1,4,7,12 values).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline Total Nap Time Per Week Measured by Actigraphy Averaged Over the 12 Week Double Blind Study Period</measure>
    <time_frame>Baseline (week 0), Day 1 (post first dose) - week 12</time_frame>
    <description>Change from baseline in the total nap time per week for subjects who napped during the baseline period. Change is calculated as the average over the double blind period (average of post-dose values from weeks 1,4,7,12) minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Total Nap Time Per Week Measured by Actigraphy at Various Study Time Points</measure>
    <time_frame>Baseline (week 0), Weeks 1,4,7,12,13,15</time_frame>
    <description>Change from baseline in the total nap time per week for subjects who napped during the baseline period. Participants who wore an actigraph wrist monitor to record rest and activity cycles are included; a Central Reader calculated sleep parameters. The change is calculated as time point value minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Total Nap Time Per Week Measured by Actigraphy at Various Study Time Points.</measure>
    <time_frame>Week 0,1,4,7,12,13,15</time_frame>
    <description>The total nap time per week for subjects who napped during the baseline period. Mean values are reported at baseline(week 0), double-blind phase(weeks 1,4,7,12), single-blind follow-up(week 13), non-drug treatment follow-up(week 15), and the average for the double-blind phase(average of weeks 1,4,7,12 values).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Total Nap Time Per Week as a Percentage of Total Asleep Time Measured by Actigraphy and Averaged Over the 12 Week Double Blind Study Period.</measure>
    <time_frame>Baseline (week 0), Day 1 (post first dose) - week 12</time_frame>
    <description>Change from baseline in the total time spent napping per week as a percent of the total time asleep for subjects who napped during the baseline period. Change is calculated as the average over the double blind period (average of post-dose values from weeks 1,4,7,12) minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Total Nap Time Per Week as a Percentage of Total Asleep Time as Measured by Actigraphy at Various Study Time Points</measure>
    <time_frame>Baseline (week 0), Weeks 1,4,7,12,13,15</time_frame>
    <description>Change from baseline in total time spent napping per week as a percent of total time asleep for subjects who napped during the baseline period. Change is calculated as time point value minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Total Nap Time Per Week as a Percentage of Total Asleep Time Measured Using Actigraphy at Various Study Time Points</measure>
    <time_frame>Week 0,1,4,7,12,13,15</time_frame>
    <description>The total time spent napping per week as a percent of the total time asleep for subjects who napped during the baseline period. Mean values reported: baseline(week 0), double-blind phase(weeks 1,4,7,12), single-blind follow-up(week 13), non-drug treatment follow-up(week 15) &amp; average for double-blind phase(average of weeks 1,4,7,12 values).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Insomnia Severity Index Total Score Averaged Over the 12 Week Double Blind Study Period</measure>
    <time_frame>Baseline (week 0), Day 1 (post first dose) - week 12</time_frame>
    <description>Change from baseline in the Insomnia Severity Index Total Score which ranges from 0-28. Lower scores represent better sleep. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Insomnia Severity Index Total Score at Various Study Time Points</measure>
    <time_frame>Baseline (week 0), Weeks 3,6,9,12,14,16</time_frame>
    <description>Change from baseline in the Insomnia Severity Index Total Score which ranges from 0-28. Lower scores represent better sleep. The change is calculated as time point value minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Insomnia Severity Index Total Scores at Various Study Time Points</measure>
    <time_frame>Weeks 0,3,6,9,12,14,16</time_frame>
    <description>The Insomnia Severity Index Total Score ranges from 0-28. Lower scores represent better sleep. Mean values are reported at baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the double-blind phase(average of weeks 3,6,9,12 values).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Physical Component Summary of the Short Form-36 Scale</measure>
    <time_frame>Baseline (week 0), Weeks 6, 12, 16</time_frame>
    <description>Physical component summary of Short Form-36 Scale measures subject's perception of their physical health, where the normal mean for general US population is 50.Scores above/below 50 represent better than/worse than the general US population. Higher scores represent better outcomes. Change is calculated as time point value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Physical Component Summary of the Short Form-36 Scale Scores.</measure>
    <time_frame>Weeks 0,6,12,16</time_frame>
    <description>This scale measures subject's perception of their physical health, where the normal mean for general US population is 50.Scores above/below 50 represent better/worse than general US population. Change calculated as time point value minus baseline value: baseline(week0), double-blind (weeks 6,12)and non-drug treatment follow-up(week16).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Mental Component Summary of the Short Form-36 Scale Scores</measure>
    <time_frame>Baseline (week 0), Weeks 6,12,16</time_frame>
    <description>Mental component summary of Short Form-36 Scale measures subject's perception of their physical health, where the normal mean for general US population is 50. Scores above/below 50 represent better than/worse than the general US population. Higher scores represent better outcomes. Change is calculated as time point value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Mental Component Summary of the Short Form-36 Scale Scores</measure>
    <time_frame>Weeks 0,6,12,16</time_frame>
    <description>This scale measures subject's perception of their physical health, where normal mean for general US population is 50. Scores above/below 50 represent better/worse than general US population. Change calculated: time point value minus baseline value. Mean values: baseline(week0), double-blind phase(weeks 6,12)&amp; non-drug treatment follow-up(week 16).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Sheehan Disability Scale Total Score.</measure>
    <time_frame>Baseline (week 0), Weeks 6,12,14,16</time_frame>
    <description>Sheehan Disability Scale Total Score (range 0-30)measures subject's level of disability &amp; includes: work/school, social life, family life/home responsibilities, days lost &amp;days underproductive; higher scores represent higher degree of disability/impairment. Change is calculated as time point value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Sheehan Disability Total Scores</measure>
    <time_frame>Weeks 0,6,12,14,16</time_frame>
    <description>Sheehan Disability Scale Total Score (range 0-30) measures subject's level of disability; includes work/school, social life, family life/home responsibilities, days lost, days underproductive; higher scores represent higher degree of disability/impairment. Mean values reported: baseline, double-blind(weeks 6,12)&amp; follow-up(weeks 14,16).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">388</enrollment>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Week -2 to day 0 single blind one tablet placebo in the evening. Double blind period: Day 1 to Week 12 double blind one tablet placebo in the evening. Follow up period: two weeks (Weeks 13-14) single blind one tablet placebo in evening, and two weeks (Weeks 15-16) no drug washout.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eszopiclone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Week -2 to day 0 single blind one tablet placebo in evening. Double Blind period: Day 1 to Week 12 double blind one tablet 2 mg of eszopiclone in evening. Follow up period consists of two weeks (Weeks 13-14) single blind one tablet placebo in evening, and two weeks (Weeks 15-16) no drug washout.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eszopiclone</intervention_name>
    <description>2 mg tablet once per day in the evening</description>
    <arm_group_label>Eszopiclone</arm_group_label>
    <other_name>Lunesta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet one per day in the evening.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Eszopiclone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects with primary chronic insomnia. Subject is otherwise in good
             general health, based on screening physical examination and medical history.

        Exclusion Criteria:

          -  Subject has recent history of known clinically significant abnormal laboratory
             findings.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director, CNS</last_name>
    <role>Study Chair</role>
    <affiliation>Sunovion</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80918</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Florida</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coral Springs</city>
        <state>Florida</state>
        <zip>33065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ft. Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34238</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60634</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vernon Hills</city>
        <state>Illinois</state>
        <zip>60061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <zip>66206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Crestview Hills</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Braintree</city>
        <state>Massachusetts</state>
        <zip>02184</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newton</city>
        <state>Massachusetts</state>
        <zip>02459</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Florissant</city>
        <state>Missouri</state>
        <zip>63031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>New Jersey</state>
        <zip>08690</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <zip>28562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mogadore</city>
        <state>Ohio</state>
        <zip>44260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scotland</city>
        <state>Pennsylvania</state>
        <zip>17254</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anderson Pharmaceutical Research</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29521</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Simpsonville</city>
        <state>South Carolina</state>
        <zip>29681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78238</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita Falls</city>
        <state>Texas</state>
        <zip>76309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ancoli-Israel S, Krystal AD, McCall WV, Schaefer K, Wilson A, Claus R, Rubens R, Roth T. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep. 2010 Feb;33(2):225-34.</citation>
    <PMID>20175406</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2006</study_first_submitted>
  <study_first_submitted_qc>October 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2006</study_first_posted>
  <results_first_submitted>February 13, 2009</results_first_submitted>
  <results_first_submitted_qc>April 6, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 2, 2009</results_first_posted>
  <last_update_submitted>February 12, 2016</last_update_submitted>
  <last_update_submitted_qc>February 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>insomnia</keyword>
  <keyword>chronic</keyword>
  <keyword>primary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eszopiclone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>823 participants were screened. Two participants in each arm completed all assessments for the double blind period but discontinued before starting the follow up period (withdrew consent; did not take any single blind medication in follow up period).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo tablets</description>
        </group>
        <group group_id="P2">
          <title>Eszopiclone</title>
          <description>Eszopiclone 2 mg tablets</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double Blind Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="194"/>
                <participants group_id="P2" count="194"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
                <participants group_id="P2" count="147"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Didnt Meet Entry/Randomization Criteria</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow up:2 Week Placebo, 2 Week no Drug</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="146">Two subjects withdrew consent prior to starting the follow up period.</participants>
                <participants group_id="P2" count="145">Two subjects withdrew consent prior to starting the follow up period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="143"/>
                <participants group_id="P2" count="144"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo tablets</description>
        </group>
        <group group_id="B2">
          <title>Eszopiclone</title>
          <description>Eszopiclone 2 mg tablets</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="194"/>
            <count group_id="B2" value="194"/>
            <count group_id="B3" value="388"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="194"/>
                    <measurement group_id="B2" value="194"/>
                    <measurement group_id="B3" value="388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.4" spread="5.2"/>
                    <measurement group_id="B2" value="71.6" spread="5.0"/>
                    <measurement group_id="B3" value="72.0" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="181"/>
                    <measurement group_id="B2" value="178"/>
                    <measurement group_id="B3" value="359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="194"/>
                    <measurement group_id="B2" value="194"/>
                    <measurement group_id="B3" value="388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>Body mass index (BMI) is measure of body fat based on height and weight that applies to both adult men and women</description>
          <units>Kilograms/Meters squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.28" spread="4.98"/>
                    <measurement group_id="B2" value="28.25" spread="4.90"/>
                    <measurement group_id="B3" value="27.76" spread="4.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>Centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165.90" spread="9.83"/>
                    <measurement group_id="B2" value="164.70" spread="10.04"/>
                    <measurement group_id="B3" value="165.30" spread="9.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <description>Participant Weight in Kilograms</description>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.44" spread="17.07"/>
                    <measurement group_id="B2" value="76.98" spread="16.72"/>
                    <measurement group_id="B3" value="76.21" spread="16.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Subject-Reported Total Sleep Time (TST) Averaged Over the 12 Week Double Blind Study Period.</title>
        <description>The difference between the total sleep time at baseline and the average total sleep time over the double blind period(average of post-dose values from weeks 3,6,9,12) reported by the participant. The change is calculated as the average over the double blind period minus the baseline value.</description>
        <time_frame>Baseline (week 0), Day 1 (post first dose)-12 weeks</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward. Change calculated as the post-dose measure minus the baseline measure. Number of participants in each arm 194, 194.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Subject-Reported Total Sleep Time (TST) Averaged Over the 12 Week Double Blind Study Period.</title>
          <description>The difference between the total sleep time at baseline and the average total sleep time over the double blind period(average of post-dose values from weeks 3,6,9,12) reported by the participant. The change is calculated as the average over the double blind period minus the baseline value.</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward. Change calculated as the post-dose measure minus the baseline measure. Number of participants in each arm 194, 194.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.18" spread="50.02"/>
                    <measurement group_id="O2" value="63.24" spread="52.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiple comparisons not applied due to only two treatments in the study.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and site type as fixed effects and the baseline as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Subject-reported Total Sleep Time at Various Study Time Points.</title>
        <description>The difference between the total sleep time at baseline and at different time points in the double-blind period (weeks 3,6,9,12), the single-blind follow-up (week 14) and the non-drug treatment follow-up (week 16). The change is calculated as the time point value minus the baseline value.</description>
        <time_frame>Weeks 0, 3, 6, 9, 12, 14, 16</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward. Change calculated as the post-dose measure minus the baseline measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Subject-reported Total Sleep Time at Various Study Time Points.</title>
          <description>The difference between the total sleep time at baseline and at different time points in the double-blind period (weeks 3,6,9,12), the single-blind follow-up (week 14) and the non-drug treatment follow-up (week 16). The change is calculated as the time point value minus the baseline value.</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward. Change calculated as the post-dose measure minus the baseline measure.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 3 (n=191,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.65" spread="42.34" lower_limit="13.68" upper_limit="25.72"/>
                    <measurement group_id="O2" value="51.02" spread="46.43" lower_limit="44.88" upper_limit="56.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=191,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.47" spread="53.31" lower_limit="25.29" upper_limit="39.67"/>
                    <measurement group_id="O2" value="61.91" spread="54.15" lower_limit="56.18" upper_limit="70.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 (n=191,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.73" spread="57.73" lower_limit="30.99" upper_limit="46.75"/>
                    <measurement group_id="O2" value="69.00" spread="61.58" lower_limit="63.00" upper_limit="78.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=191,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.86" spread="60.74" lower_limit="33.16" upper_limit="49.63"/>
                    <measurement group_id="O2" value="70.97" spread="62.18" lower_limit="64.95" upper_limit="81.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=191,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.78" spread="66.52" lower_limit="35.54" upper_limit="53.54"/>
                    <measurement group_id="O2" value="50.12" spread="68.25" lower_limit="44.83" upper_limit="62.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=191,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.43" spread="67.68" lower_limit="31.36" upper_limit="49.07"/>
                    <measurement group_id="O2" value="47.17" spread="63.68" lower_limit="42.89" upper_limit="60.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Subject-reported Total Sleep Time in Minutes at Various Study Time Points.</title>
        <description>The mean total minutes asleep each night at different time points: baseline(week 0), double-blind phase(weeks 3,6,9,12), the single-blind follow-up(week 14),the non-drug treatment follow-up(week 16), and the double-blind average(average of weeks 3,6,9,12 values).</description>
        <time_frame>Weeks 0, 3, 6, 9, 12, 14, 16</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Subject-reported Total Sleep Time in Minutes at Various Study Time Points.</title>
          <description>The mean total minutes asleep each night at different time points: baseline(week 0), double-blind phase(weeks 3,6,9,12), the single-blind follow-up(week 14),the non-drug treatment follow-up(week 16), and the double-blind average(average of weeks 3,6,9,12 values).</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (n=192,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="294.03" spread="63.30"/>
                    <measurement group_id="O2" value="297.86" spread="56.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n=192,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="314.53" spread="63.52"/>
                    <measurement group_id="O2" value="347.37" spread="57.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="326.25" spread="65.41"/>
                    <measurement group_id="O2" value="358.72" spread="61.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 (n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="332.47" spread="65.25"/>
                    <measurement group_id="O2" value="365.80" spread="64.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="334.69" spread="69.91"/>
                    <measurement group_id="O2" value="367.75" spread="66.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 3,6,9,12 (double blind average)(n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="326.98" spread="62.88"/>
                    <measurement group_id="O2" value="360.08" spread="59.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="336.55" spread="71.13"/>
                    <measurement group_id="O2" value="347.12" spread="72.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="331.29" spread="72.53"/>
                    <measurement group_id="O2" value="344.20" spread="74.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Subject-reported Sleep Latency (SL) Averaged Over the 12 Week Double Blind Period.</title>
        <description>Sleep latency answers how long it takes to fall asleep. The difference between the sleep latency at baseline and the average sleep latency over the double blind period(average of post-dose values from weeks 3,6,9,12) reported by the participant. The change is calculated as the average over the double blind period minus the baseline value.</description>
        <time_frame>Baseline (week 0), Day 1 (post first dose) - Week12</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward. Number of participants in each arm 194, 194.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Subject-reported Sleep Latency (SL) Averaged Over the 12 Week Double Blind Period.</title>
          <description>Sleep latency answers how long it takes to fall asleep. The difference between the sleep latency at baseline and the average sleep latency over the double blind period(average of post-dose values from weeks 3,6,9,12) reported by the participant. The change is calculated as the average over the double blind period minus the baseline value.</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward. Number of participants in each arm 194, 194.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.92" spread="46.99"/>
                    <measurement group_id="O2" value="-24.62" spread="46.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0014</p_value>
            <p_value_desc>Multiple comparisons not applied due to only two treatments in the study.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and site type as fixed effects and the baseline as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Subject-reported Sleep Latency at Various Study Time Points</title>
        <description>Sleep latency answers the question: How long did it take you to fall asleep last night? The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
        <time_frame>Baseline (week 0), Weeks 3,6,9,12,14,16</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Subject-reported Sleep Latency at Various Study Time Points</title>
          <description>Sleep latency answers the question: How long did it take you to fall asleep last night? The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 3 (n=191,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.34" spread="41.97" lower_limit="0.78" upper_limit="0.90"/>
                    <measurement group_id="O2" value="-21.89" spread="44.38" lower_limit="0.64" upper_limit="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=191,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.69" spread="52.08" lower_limit="0.70" upper_limit="0.83"/>
                    <measurement group_id="O2" value="-24.13" spread="49.20" lower_limit="0.59" upper_limit="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 (n=191,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.02" spread="50.75" lower_limit="0.66" upper_limit="0.79"/>
                    <measurement group_id="O2" value="-24.21" spread="52.62" lower_limit="0.57" upper_limit="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=191,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.54" spread="54.14" lower_limit="0.64" upper_limit="0.78"/>
                    <measurement group_id="O2" value="-28.35" spread="49.72" lower_limit="0.53" upper_limit="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=191,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.08" spread="58.99" lower_limit="0.61" upper_limit="0.75"/>
                    <measurement group_id="O2" value="-17.00" spread="55.55" lower_limit="0.62" upper_limit="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=191,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.61" spread="55.22" lower_limit="0.62" upper_limit="0.76"/>
                    <measurement group_id="O2" value="-18.73" spread="51.67" lower_limit="0.60" upper_limit="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Subject-reported Sleep Latency Reported at Various Study Time Points.</title>
        <description>Sleep latency answers the question: How long did it take you to fall asleep last night? Mean values are reported at baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the entire double-blind phase(average of weeks 3,6,9,12 values).</description>
        <time_frame>Weeks 0,3,6,9,12,14,16</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Subject-reported Sleep Latency Reported at Various Study Time Points.</title>
          <description>Sleep latency answers the question: How long did it take you to fall asleep last night? Mean values are reported at baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the entire double-blind phase(average of weeks 3,6,9,12 values).</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (n=192,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.17" spread="74.08"/>
                    <measurement group_id="O2" value="75.68" spread="56.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n=192,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.80" spread="64.51"/>
                    <measurement group_id="O2" value="54.69" spread="46.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.57" spread="60.06"/>
                    <measurement group_id="O2" value="52.11" spread="48.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 (n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.23" spread="52.05"/>
                    <measurement group_id="O2" value="51.75" spread="51.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.69" spread="51.84"/>
                    <measurement group_id="O2" value="47.66" spread="39.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 3,6,9,12 (double blind average)(n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.32" spread="54.82"/>
                    <measurement group_id="O2" value="51.51" spread="43.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.23" spread="49.94"/>
                    <measurement group_id="O2" value="58.89" spread="45.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.62" spread="51.99"/>
                    <measurement group_id="O2" value="57.17" spread="45.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Subject-reported Wake Time After Sleep Onset (WASO) Averaged Over the 12 Week Double-blind Study Period.</title>
        <description>Wake time after sleep onset (WASO) is the time spent awake from sleep onset to final awakening. The difference between WASO at baseline and the average WASO over the double blind period(average of post-dose values from weeks 3,6,9,12). The change is calculated as the average over the double blind period minus the baseline value.</description>
        <time_frame>Baseline (week 0), Day 1 (post first dose) -week 12</time_frame>
        <population>Intent to treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last observation carried forward (LOCF). Number of participants in each arm 194, 194.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Subject-reported Wake Time After Sleep Onset (WASO) Averaged Over the 12 Week Double-blind Study Period.</title>
          <description>Wake time after sleep onset (WASO) is the time spent awake from sleep onset to final awakening. The difference between WASO at baseline and the average WASO over the double blind period(average of post-dose values from weeks 3,6,9,12). The change is calculated as the average over the double blind period minus the baseline value.</description>
          <population>Intent to treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last observation carried forward (LOCF). Number of participants in each arm 194, 194.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.75" spread="38.45"/>
                    <measurement group_id="O2" value="-36.40" spread="41.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiple comparisons not applied due to only two treatments in the study.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and site type as fixed effects and the baseline as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Subject-reported Wake Time After Sleep Onset (WASO) at Various Study Time Points.</title>
        <description>Wake time after sleep onset is the time spent awake from sleep onset to final awakening. The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
        <time_frame>Baseline (week 0), weeks 3,6,9,12,14,16</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Subject-reported Wake Time After Sleep Onset (WASO) at Various Study Time Points.</title>
          <description>Wake time after sleep onset is the time spent awake from sleep onset to final awakening. The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 3 (n=188,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.55" spread="35.80" lower_limit="0.73" upper_limit="0.93"/>
                    <measurement group_id="O2" value="-29.26" spread="37.68" lower_limit="0.48" upper_limit="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=189,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.46" spread="39.01" lower_limit="0.65" upper_limit="0.86"/>
                    <measurement group_id="O2" value="-36.57" spread="43.11" lower_limit="0.39" upper_limit="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 (n=189,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.67" spread="44.13" lower_limit="0.57" upper_limit="0.77"/>
                    <measurement group_id="O2" value="-40.32" spread="45.12" lower_limit="0.36" upper_limit="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=189,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.13" spread="43.39" lower_limit="0.54" upper_limit="0.74"/>
                    <measurement group_id="O2" value="-39.61" spread="46.48" lower_limit="0.35" upper_limit="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=189,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.72" spread="45.00" lower_limit="0.46" upper_limit="0.64"/>
                    <measurement group_id="O2" value="-32.27" spread="47.55" lower_limit="0.39" upper_limit="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=189,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.18" spread="48.06" lower_limit="0.45" upper_limit="0.64"/>
                    <measurement group_id="O2" value="-31.13" spread="51.35" lower_limit="0.38" upper_limit="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Subject-reported Wake Time After Sleep Onset (WASO) at Various Study Time Points</title>
        <description>Wake time after sleep onset is the time spent awake from sleep onset to final awakening. Mean values are reported at baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the entire double-blind phase(average of weeks 3,6,9,12 values).</description>
        <time_frame>Weeks 0,3,6,9,12,14,16</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Subject-reported Wake Time After Sleep Onset (WASO) at Various Study Time Points</title>
          <description>Wake time after sleep onset is the time spent awake from sleep onset to final awakening. Mean values are reported at baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the entire double-blind phase(average of weeks 3,6,9,12 values).</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (n=190,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.86" spread="51.77"/>
                    <measurement group_id="O2" value="92.66" spread="58.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n=190,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.17" spread="49.63"/>
                    <measurement group_id="O2" value="64.33" spread="45.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.86" spread="48.82"/>
                    <measurement group_id="O2" value="56.49" spread="44.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 (n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.33" spread="49.71"/>
                    <measurement group_id="O2" value="52.75" spread="42.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.02" spread="50.44"/>
                    <measurement group_id="O2" value="53.45" spread="44.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 3,6,9,12 (double blind average)(n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.59" spread="47.52"/>
                    <measurement group_id="O2" value="56.68" spread="42.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.39" spread="51.87"/>
                    <measurement group_id="O2" value="60.71" spread="47.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.27" spread="54.61"/>
                    <measurement group_id="O2" value="61.84" spread="48.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Subject-reported Number of Awakenings Averaged Over the 12 Week Double Blind Study Period.</title>
        <description>The number of awakenings is the number of times a subject wakes up between the initial onset of sleep and the final awakening. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</description>
        <time_frame>Baseline (week 0), Day 1 (post first dose) - Week12</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward. Number of participants in each arm 194, 194.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Subject-reported Number of Awakenings Averaged Over the 12 Week Double Blind Study Period.</title>
          <description>The number of awakenings is the number of times a subject wakes up between the initial onset of sleep and the final awakening. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward. Number of participants in each arm 194, 194.</population>
          <units>number of awakenings</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.72"/>
                    <measurement group_id="O2" value="-0.56" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <p_value_desc>Multiple comparisons not applied due to only two treatments in study.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and site type as fixed effects and the baseline as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of Subject-reported Awakenings at Various Study Time Points.</title>
        <description>The number of awakenings refers to the number of times a subject wakes up between the initial onset of sleep and the final awakening. The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
        <time_frame>Baseline (week 0), Weeks 3,6,9,12,14,16</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Subject-reported Awakenings at Various Study Time Points.</title>
          <description>The number of awakenings refers to the number of times a subject wakes up between the initial onset of sleep and the final awakening. The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
          <units>number of awakenings</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 3 (n=188,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread=".63" lower_limit="-0.27" upper_limit="-0.10"/>
                    <measurement group_id="O2" value="-0.46" spread="0.70" lower_limit="-0.51" upper_limit="-0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=189,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="0.77" lower_limit="-0.38" upper_limit="-0.17"/>
                    <measurement group_id="O2" value="-0.56" spread="0.83" lower_limit="-0.64" upper_limit="-0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 (n=189,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.81" lower_limit="-0.47" upper_limit="-0.26"/>
                    <measurement group_id="O2" value="-0.57" spread="0.88" lower_limit="-0.66" upper_limit="-0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=189,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.83" lower_limit="-0.50" upper_limit="-0.28"/>
                    <measurement group_id="O2" value="-0.65" spread="0.90" lower_limit="-0.75" upper_limit="-0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=189,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.85" lower_limit="-0.54" upper_limit="-0.30"/>
                    <measurement group_id="O2" value="-0.46" spread="0.96" lower_limit="-0.57" upper_limit="-0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=189,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.87" lower_limit="-0.53" upper_limit="-0.29"/>
                    <measurement group_id="O2" value="-0.44" spread="0.97" lower_limit="-0.57" upper_limit="-0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Awakenings (Subject-reported) at Various Study Time Points</title>
        <description>Number of awakenings is number of times a subject wakes up between initial onset of sleep and final awakening. Mean values are reported at baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the double-blind phase(average of weeks 3,6,9,12 values).</description>
        <time_frame>Weeks 0,3,6,9,12,14,16</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Awakenings (Subject-reported) at Various Study Time Points</title>
          <description>Number of awakenings is number of times a subject wakes up between initial onset of sleep and final awakening. Mean values are reported at baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the double-blind phase(average of weeks 3,6,9,12 values).</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
          <units>number of awakenings</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (n=190,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread="1.00"/>
                    <measurement group_id="O2" value="2.10" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n=190,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.78" spread="0.91"/>
                    <measurement group_id="O2" value="1.66" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" spread="0.93"/>
                    <measurement group_id="O2" value="1.55" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 (n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="0.94"/>
                    <measurement group_id="O2" value="1.54" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" spread="0.94"/>
                    <measurement group_id="O2" value="1.46" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 3,6,9,12 (double blind average)(n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.68" spread="0.90"/>
                    <measurement group_id="O2" value="1.55" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" spread="0.99"/>
                    <measurement group_id="O2" value="1.65" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" spread="0.97"/>
                    <measurement group_id="O2" value="1.66" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Subject-reported Quality of Sleep Averaged Over the 12 Week Double Blind Study Period</title>
        <description>Quality of sleep was rated by participants on a scale of 0-10, with higher scores representing better quality sleep. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</description>
        <time_frame>Baseline (week 0), Day 1 (post first dose) - Week12</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward. Number of participants in each arm 194, 194.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Subject-reported Quality of Sleep Averaged Over the 12 Week Double Blind Study Period</title>
          <description>Quality of sleep was rated by participants on a scale of 0-10, with higher scores representing better quality sleep. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward. Number of participants in each arm 194, 194.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="1.35"/>
                    <measurement group_id="O2" value="1.39" spread="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiple comparisons not applied due to only two treatments in the study.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and site type as fixed effects and the baseline as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Subject-reported Quality of Sleep at Various Study Time Points.</title>
        <description>Sleep quality was rated by subjects on a scale from 0-10, with higher scores representing better quality sleep. The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
        <time_frame>Baseline (week 0), Weeks 3,6,9,12,14,16</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Subject-reported Quality of Sleep at Various Study Time Points.</title>
          <description>Sleep quality was rated by subjects on a scale from 0-10, with higher scores representing better quality sleep. The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 3 (n=188,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="0.98" lower_limit="0.24" upper_limit="0.52"/>
                    <measurement group_id="O2" value="1.12" spread="1.18" lower_limit="0.94" upper_limit="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=189,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" spread="1.31" lower_limit="0.49" upper_limit="0.83"/>
                    <measurement group_id="O2" value="1.35" spread="1.43" lower_limit="1.16" upper_limit="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 (n=189,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="1.58" lower_limit="0.68" upper_limit="1.06"/>
                    <measurement group_id="O2" value="1.52" spread="1.62" lower_limit="1.31" upper_limit="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=189,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" spread="1.77" lower_limit="0.78" upper_limit="1.19"/>
                    <measurement group_id="O2" value="1.57" spread="1.73" lower_limit="1.35" upper_limit="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=189,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" spread="1.88" lower_limit="0.89" upper_limit="1.34"/>
                    <measurement group_id="O2" value="1.26" spread="2.07" lower_limit="1.03" upper_limit="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=189, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" spread="1.96" lower_limit="0.78" upper_limit="1.23"/>
                    <measurement group_id="O2" value="1.22" spread="2.06" lower_limit="1.03" upper_limit="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Ratings of Subject-reported Quality of Sleep at Various Study Time Points</title>
        <description>Quality of sleep was rated by participants on a scale of 0-10, with higher scores representing better quality sleep. Mean values are reported at baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the double-blind phase(average of weeks 3,6,9,12 values).</description>
        <time_frame>weeks 0,3,6,9,12,14,16</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Ratings of Subject-reported Quality of Sleep at Various Study Time Points</title>
          <description>Quality of sleep was rated by participants on a scale of 0-10, with higher scores representing better quality sleep. Mean values are reported at baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the double-blind phase(average of weeks 3,6,9,12 values).</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (n=190,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.84" spread="1.83"/>
                    <measurement group_id="O2" value="4.68" spread="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n=190,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.22" spread="1.62"/>
                    <measurement group_id="O2" value="5.77" spread="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.48" spread="1.56"/>
                    <measurement group_id="O2" value="6.01" spread="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 (n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.67" spread="1.57"/>
                    <measurement group_id="O2" value="6.17" spread="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.78" spread="1.58"/>
                    <measurement group_id="O2" value="6.22" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 3,6,9,12 (double blind average)(n=192, 193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.54" spread="1.50"/>
                    <measurement group_id="O2" value="6.04" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.88" spread="1.60"/>
                    <measurement group_id="O2" value="5.91" spread="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.73" spread="1.65"/>
                    <measurement group_id="O2" value="5.88" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Subject-Reported Depth of Sleep for the Average Reported During the Double-blind Period.</title>
        <description>Depth of sleep was reported by study participants using a scale from 0-10, with higher scores representing better sleep. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</description>
        <time_frame>Baseline (week 0), Day 1 (post first dose) - week 12</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward. Number of participants in each arm 194, 194.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Subject-Reported Depth of Sleep for the Average Reported During the Double-blind Period.</title>
          <description>Depth of sleep was reported by study participants using a scale from 0-10, with higher scores representing better sleep. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward. Number of participants in each arm 194, 194.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" spread="1.33"/>
                    <measurement group_id="O2" value="1.33" spread="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiple comparisons not applied due to only two treatments in the study.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and site type as fixed effects and the baseline as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Subject-reported Depth of Sleep at Various Study Time Points</title>
        <description>Depth of sleep was reported by study participants using a scale from 0-10, with higher scores representing better sleep. The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
        <time_frame>Baseline (week 0), Weeks 3,6,9,12,14,16</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Subject-reported Depth of Sleep at Various Study Time Points</title>
          <description>Depth of sleep was reported by study participants using a scale from 0-10, with higher scores representing better sleep. The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 3 (n=188, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="0.97"/>
                    <measurement group_id="O2" value="1.07" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=189, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" spread="1.29"/>
                    <measurement group_id="O2" value="1.30" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 (n=189, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" spread="1.54"/>
                    <measurement group_id="O2" value="1.46" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=189, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" spread="1.74"/>
                    <measurement group_id="O2" value="1.49" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=189,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="1.88"/>
                    <measurement group_id="O2" value="1.23" spread="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=189,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" spread="1.96"/>
                    <measurement group_id="O2" value="1.15" spread="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Subject-reported Depth of Sleep at Various Study Time Points</title>
        <description>Depth of sleep was reported by study participants using a scale from 0-10, with higher scores representing better sleep. Mean values reported: baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the double-blind phase(average of weeks 3,6,9,12 values).</description>
        <time_frame>weeks 0,3,6,9,12,14,16</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Subject-reported Depth of Sleep at Various Study Time Points</title>
          <description>Depth of sleep was reported by study participants using a scale from 0-10, with higher scores representing better sleep. Mean values reported: baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the double-blind phase(average of weeks 3,6,9,12 values).</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (n=190,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.87" spread="1.88"/>
                    <measurement group_id="O2" value="4.72" spread="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n=190,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.29" spread="1.62"/>
                    <measurement group_id="O2" value="5.76" spread="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.51" spread="1.58"/>
                    <measurement group_id="O2" value="6.00" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 (n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.71" spread="1.58"/>
                    <measurement group_id="O2" value="6.15" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=192, 193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.82" spread="1.59"/>
                    <measurement group_id="O2" value="6.18" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 3,6,9,12 (double blind average)(n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.58" spread="1.52"/>
                    <measurement group_id="O2" value="6.02" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.89" spread="1.63"/>
                    <measurement group_id="O2" value="5.92" spread="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.76" spread="1.69"/>
                    <measurement group_id="O2" value="5.84" spread="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Subject-reported Daytime Alertness Averaged Over the 12 Week Double Blind Study Period</title>
        <description>Daytime alertness was rated by study participants on a scale of 0-10, with higher scores representing better alertness. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</description>
        <time_frame>Baseline (week 0), Day 1 (post first dose) - week 12</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward. Number of participants in each arm 194, 194.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Subject-reported Daytime Alertness Averaged Over the 12 Week Double Blind Study Period</title>
          <description>Daytime alertness was rated by study participants on a scale of 0-10, with higher scores representing better alertness. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward. Number of participants in each arm 194, 194.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61" spread="1.30"/>
                    <measurement group_id="O2" value="1.02" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiple comparisons not applied due to only two treatments in the study.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and site type as fixed effects and the baseline as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Subject-reported Daytime Alertness at Various Study Time Points</title>
        <description>Daytime alertness was rated by study participants on a scale of 0-10, with higher scores representing better alertness. The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
        <time_frame>Baseline (week 0), Weeks 3,6,9,12,14,16</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Subject-reported Daytime Alertness at Various Study Time Points</title>
          <description>Daytime alertness was rated by study participants on a scale of 0-10, with higher scores representing better alertness. The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 3 (n=189,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="0.90"/>
                    <measurement group_id="O2" value="0.76" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=189,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="1.28"/>
                    <measurement group_id="O2" value="0.99" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 (n=189,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" spread="1.53"/>
                    <measurement group_id="O2" value="1.10" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=189,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78" spread="1.72"/>
                    <measurement group_id="O2" value="1.21" spread="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=189,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="1.81"/>
                    <measurement group_id="O2" value="1.05" spread="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=189,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78" spread="1.89"/>
                    <measurement group_id="O2" value="0.97" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Subject-reported Daytime Alertness at Various Study Time Points.</title>
        <description>Daytime alertness was rated by study participants on a scale of 0-10, with higher scores representing better alertness. Mean values reported: baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the double-blind phase(average of weeks 3,6,9,12 values).</description>
        <time_frame>Weeks 0,3,6,9,12,14,16</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Subject-reported Daytime Alertness at Various Study Time Points.</title>
          <description>Daytime alertness was rated by study participants on a scale of 0-10, with higher scores representing better alertness. Mean values reported: baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the double-blind phase(average of weeks 3,6,9,12 values).</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.34" spread="1.97"/>
                    <measurement group_id="O2" value="5.42" spread="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n=190,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.74" spread="1.72"/>
                    <measurement group_id="O2" value="6.18" spread="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=190,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.89" spread="1.57"/>
                    <measurement group_id="O2" value="6.41" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 (n=190,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.06" spread="1.51"/>
                    <measurement group_id="O2" value="6.52" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=190,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.13" spread="1.51"/>
                    <measurement group_id="O2" value="6.64" spread="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 3,6,9,12 (double blind average)(n=190,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.95" spread="1.50"/>
                    <measurement group_id="O2" value="6.44" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=190,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.19" spread="1.52"/>
                    <measurement group_id="O2" value="6.47" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=190,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.13" spread="1.59"/>
                    <measurement group_id="O2" value="6.39" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Subject-Reported Ability to Function Averaged Over the 12 Week Double Blind Period</title>
        <description>Ability to function was rated by study participants on a scale of 0-10, with higher scores representing better ability to function. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</description>
        <time_frame>Baseline (week 0), Day 1 (post first dose) - week 12</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward. Number of participants in each arm 194, 194.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Subject-Reported Ability to Function Averaged Over the 12 Week Double Blind Period</title>
          <description>Ability to function was rated by study participants on a scale of 0-10, with higher scores representing better ability to function. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward. Number of participants in each arm 194, 194.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="1.29"/>
                    <measurement group_id="O2" value="0.91" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiple comparisons not applied due to only two treatments in the study.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and site type as fixed effects and the baseline as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Subject-reported Ability to Function at Various Study Time Points</title>
        <description>Ability to function was rated by study participants on a scale of 0-10, with higher scores representing better ability to function. The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
        <time_frame>Baseline (week 0), Weeks 3,6,9,12,14,16</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Subject-reported Ability to Function at Various Study Time Points</title>
          <description>Ability to function was rated by study participants on a scale of 0-10, with higher scores representing better ability to function. The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 3 (n=189,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.88"/>
                    <measurement group_id="O2" value="0.69" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=189,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="1.25"/>
                    <measurement group_id="O2" value="0.87" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 (n=189,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" spread="1.54"/>
                    <measurement group_id="O2" value="0.98" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=189,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" spread="1.68"/>
                    <measurement group_id="O2" value="1.08" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=189,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="1.81"/>
                    <measurement group_id="O2" value="0.96" spread="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=189,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" spread="1.87"/>
                    <measurement group_id="O2" value="0.87" spread="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Subject-reported Ability to Function at Various Study Time Points</title>
        <description>Ability to function was rated by study participants on a scale of 0-10, with higher scores representing better ability to function. Mean values reported: baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16) &amp; average for double-blind phase(average of weeks 3,6,9,12 values).</description>
        <time_frame>Weeks 0,3,6,9,12,14,16</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Subject-reported Ability to Function at Various Study Time Points</title>
          <description>Ability to function was rated by study participants on a scale of 0-10, with higher scores representing better ability to function. Mean values reported: baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16) &amp; average for double-blind phase(average of weeks 3,6,9,12 values).</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.62" spread="2.07"/>
                    <measurement group_id="O2" value="5.69" spread="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n=190,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.98" spread="1.79"/>
                    <measurement group_id="O2" value="6.38" spread="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=190,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.09" spread="1.61"/>
                    <measurement group_id="O2" value="6.57" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 (n=190,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.24" spread="1.56"/>
                    <measurement group_id="O2" value="6.69" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=190,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.32" spread="1.54"/>
                    <measurement group_id="O2" value="6.79" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 3,6,9,12 (double blind average)(n=190,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.16" spread="1.55"/>
                    <measurement group_id="O2" value="6.61" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=190,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.38" spread="1.54"/>
                    <measurement group_id="O2" value="6.66" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=190,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.31" spread="1.62"/>
                    <measurement group_id="O2" value="6.57" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Subject-reported Ability to Concentrate Averaged Over the 12 Week Double Blind Study Period.</title>
        <description>Ability to concentrate was rated by study participants on a scale of 0-10, with higher scores representing better concentration. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</description>
        <time_frame>Baseliine (week 0), Day 1 (post first dose) - week 12</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward. Number of participants in each arm 194, 194.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Subject-reported Ability to Concentrate Averaged Over the 12 Week Double Blind Study Period.</title>
          <description>Ability to concentrate was rated by study participants on a scale of 0-10, with higher scores representing better concentration. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward. Number of participants in each arm 194, 194.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="1.30"/>
                    <measurement group_id="O2" value="0.96" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiple comparisons not applied due to only two treatments in the study.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and site type as fixed effects and the baseline as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Subject-reported Ability to Concentrate at Various Study Time Points.</title>
        <description>Ability to concentrate was rated by study participants on a scale of 0-10, with higher scores representing better concentration. The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
        <time_frame>Baseline (week 0), Weeks 3,6,9,12,14,16</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Subject-reported Ability to Concentrate at Various Study Time Points.</title>
          <description>Ability to concentrate was rated by study participants on a scale of 0-10, with higher scores representing better concentration. The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 3 (n=189,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="0.89"/>
                    <measurement group_id="O2" value="0.73" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=189,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="1.29"/>
                    <measurement group_id="O2" value="0.93" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 (n=189,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="1.53"/>
                    <measurement group_id="O2" value="1.03" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=189,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" spread="1.71"/>
                    <measurement group_id="O2" value="1.14" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=189,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" spread="1.81"/>
                    <measurement group_id="O2" value="1.00" spread="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=189,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" spread="1.89"/>
                    <measurement group_id="O2" value="0.93" spread="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Subject-reported Ability to Concentrate at Various Study Time Points</title>
        <description>Ability to concentrate was rated by study participants on a scale of 0-10, with higher scores representing better concentration. Mean values reported: baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16) &amp; average for the double-blind phase(average of weeks 3,6,9,12 values).</description>
        <time_frame>Weeks 0,3,6,9,12,14,16</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Subject-reported Ability to Concentrate at Various Study Time Points</title>
          <description>Ability to concentrate was rated by study participants on a scale of 0-10, with higher scores representing better concentration. Mean values reported: baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16) &amp; average for the double-blind phase(average of weeks 3,6,9,12 values).</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.66" spread="2.08"/>
                    <measurement group_id="O2" value="5.63" spread="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n=190,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.99" spread="1.78"/>
                    <measurement group_id="O2" value="6.37" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=190,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.10" spread="1.62"/>
                    <measurement group_id="O2" value="6.57" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 (n=190,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.27" spread="1.54"/>
                    <measurement group_id="O2" value="6.67" spread="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=190,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.33" spread="1.52"/>
                    <measurement group_id="O2" value="6.77" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 3,6,9,12 (double blind average)(n=190,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.17" spread="1.54"/>
                    <measurement group_id="O2" value="6.60" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=190,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.39" spread="1.53"/>
                    <measurement group_id="O2" value="6.64" spread="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=190,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.33" spread="1.61"/>
                    <measurement group_id="O2" value="6.56" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Subject-reported Physical Well-Being Averaged Over the 12 Week Double Blind Study Period</title>
        <description>Physical well-being was rated by study participants on a scale of 0-10, with higher scores representing better well-being. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</description>
        <time_frame>Baseline (week 0), Day 1 (post first dose) - week 12</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward. Number of participants in each arm 194, 194.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Subject-reported Physical Well-Being Averaged Over the 12 Week Double Blind Study Period</title>
          <description>Physical well-being was rated by study participants on a scale of 0-10, with higher scores representing better well-being. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward. Number of participants in each arm 194, 194.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" spread="1.28"/>
                    <measurement group_id="O2" value="0.87" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiple comparisons not applied due to only two treatments in the study.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and site type as fixed effects and the baseline as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Subject-reported Physical Well-being at Various Study Time Points.</title>
        <description>Physical well-being was rated by study participants on a scale of 0-10, with higher scores representing better well-being. The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
        <time_frame>Baseline (week 0), Weeks 3,6,9,12,14,16</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Subject-reported Physical Well-being at Various Study Time Points.</title>
          <description>Physical well-being was rated by study participants on a scale of 0-10, with higher scores representing better well-being. The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 3 (n=189,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="0.88"/>
                    <measurement group_id="O2" value="0.68" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=189,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="1.26"/>
                    <measurement group_id="O2" value="0.84" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 (n=189,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61" spread="1.52"/>
                    <measurement group_id="O2" value="0.93" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=189,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="1.71"/>
                    <measurement group_id="O2" value="1.02" spread="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=189,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" spread="1.82"/>
                    <measurement group_id="O2" value="0.89" spread="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=189,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="1.90"/>
                    <measurement group_id="O2" value="0.80" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Subject-reported Physical Well-Being at Various Study Time Points</title>
        <description>Physical well-being was rated by study participants on a scale of 0-10, with higher scores representing better well-being. Mean values reported: baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), &amp; average for double-blind phase(average of weeks 3,6,9,12 values).</description>
        <time_frame>Weeks 0,3,6,9,12,14,16</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Subject-reported Physical Well-Being at Various Study Time Points</title>
          <description>Physical well-being was rated by study participants on a scale of 0-10, with higher scores representing better well-being. Mean values reported: baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), &amp; average for double-blind phase(average of weeks 3,6,9,12 values).</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (n=192,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.45" spread="1.98"/>
                    <measurement group_id="O2" value="5.62" spread="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n=190,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.80" spread="1.74"/>
                    <measurement group_id="O2" value="6.30" spread="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=190,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.92" spread="1.57"/>
                    <measurement group_id="O2" value="6.46" spread="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 (n=190,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.06" spread="1.53"/>
                    <measurement group_id="O2" value="6.56" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=190,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.11" spread="1.52"/>
                    <measurement group_id="O2" value="6.65" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 3,6,9,12 (double blind average)(n=190,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.97" spread="1.51"/>
                    <measurement group_id="O2" value="6.49" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=190,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.18" spread="1.53"/>
                    <measurement group_id="O2" value="6.51" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=190,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.09" spread="1.61"/>
                    <measurement group_id="O2" value="6.43" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Subject-Reported Counts of Number of Naps Per Week Averaged Over the 12 Week Double Blind Study Period</title>
        <description>Change from baseline in the number of naps per week for subjects who napped during the baseline period. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</description>
        <time_frame>Baseline (week 0), Day 1 (post first dose)- week 12</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment and who napped at baseline are included. Last Observation Carried Forward. Number of participants in each arm 194, 194.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Subject-Reported Counts of Number of Naps Per Week Averaged Over the 12 Week Double Blind Study Period</title>
          <description>Change from baseline in the number of naps per week for subjects who napped during the baseline period. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment and who napped at baseline are included. Last Observation Carried Forward. Number of participants in each arm 194, 194.</population>
          <units>number of naps</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.78" spread="2.30"/>
                    <measurement group_id="O2" value="-1.23" spread="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1175</p_value>
            <p_value_desc>Multiple comparisons not applied due to only two treatments in the study.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and site type as fixed effects and the baseline as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline In Subject-Reported Counts of Number of Naps Per Week at Various Study Time Points</title>
        <description>Change from baseline in the number of naps per week for subjects who napped during the baseline period. The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
        <time_frame>Baseline (week 0), Weeks 3,6,9,12,14,16</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment and who napped at baseline are included. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline In Subject-Reported Counts of Number of Naps Per Week at Various Study Time Points</title>
          <description>Change from baseline in the number of naps per week for subjects who napped during the baseline period. The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment and who napped at baseline are included. Last Observation Carried Forward.</population>
          <units>number of naps</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 3 (n=110,92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="2.04"/>
                    <measurement group_id="O2" value="-1.15" spread="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=110,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="2.49"/>
                    <measurement group_id="O2" value="-1.26" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 (n=110, 93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.96" spread="2.67"/>
                    <measurement group_id="O2" value="-1.33" spread="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=110, 93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.96" spread="2.88"/>
                    <measurement group_id="O2" value="-1.18" spread="2.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=110,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.71" spread="2.93"/>
                    <measurement group_id="O2" value="-1.00" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=110,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.92" spread="2.79"/>
                    <measurement group_id="O2" value="-1.29" spread="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Subject-Reported Number of Naps Each Week at Various Study Time Points.</title>
        <description>The mean number of naps per week for subjects who napped during the baseline period. Mean values are reported at baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the double-blind phase(average of weeks 3,6,9,12 values).</description>
        <time_frame>Weeks 0,3,6,9,12,14,16</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment and who napped at baseline are included. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Subject-Reported Number of Naps Each Week at Various Study Time Points.</title>
          <description>The mean number of naps per week for subjects who napped during the baseline period. Mean values are reported at baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the double-blind phase(average of weeks 3,6,9,12 values).</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment and who napped at baseline are included. Last Observation Carried Forward.</population>
          <units>number of naps</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (n=111,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.03" spread="4.41"/>
                    <measurement group_id="O2" value="3.88" spread="3.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n=110,92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.67" spread="4.67"/>
                    <measurement group_id="O2" value="2.76" spread="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=110,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.26" spread="4.25"/>
                    <measurement group_id="O2" value="2.64" spread="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 (n=110,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.10" spread="4.57"/>
                    <measurement group_id="O2" value="2.57" spread="2.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=110,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.10" spread="5.05"/>
                    <measurement group_id="O2" value="2.71" spread="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 3,6,9,12 (double blind average)(n=110,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.28" spread="4.51"/>
                    <measurement group_id="O2" value="2.66" spread="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=110,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.35" spread="5.32"/>
                    <measurement group_id="O2" value="2.90" spread="3.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=110,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.14" spread="4.63"/>
                    <measurement group_id="O2" value="2.61" spread="3.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Subject-Reported Total Nap Time Per Week Averaged Over the 12 Week Double Blind Study Period</title>
        <description>Change from baseline in the total time (minutes) spent napping per week for subjects who napped during the baseline period. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</description>
        <time_frame>Baseline (week 0), Day 1 (post first dose) - week 12</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment and who napped at baseline are included. Last Observation Carried Forward. Number of participants in each arm 194, 194.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Subject-Reported Total Nap Time Per Week Averaged Over the 12 Week Double Blind Study Period</title>
          <description>Change from baseline in the total time (minutes) spent napping per week for subjects who napped during the baseline period. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment and who napped at baseline are included. Last Observation Carried Forward. Number of participants in each arm 194, 194.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.02" spread="125.59"/>
                    <measurement group_id="O2" value="-60.06" spread="156.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0717</p_value>
            <p_value_desc>Multiple comparisons not applied due to only two treatments in the study.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and site type as fixed effects and the baseline as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Subject-Reported Total Nap Time Per Week at Various Study Time Points.</title>
        <description>Change from baseline in the total time (minutes) spent napping per week for subjects who napped during the baseline period. The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
        <time_frame>Baseline (week 0), Weeks 3,6,9,12,14,16</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment and who napped at baseline are included. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Subject-Reported Total Nap Time Per Week at Various Study Time Points.</title>
          <description>Change from baseline in the total time (minutes) spent napping per week for subjects who napped during the baseline period. The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment and who napped at baseline are included. Last Observation Carried Forward.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 3 (n=110,92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.66" spread="116.53"/>
                    <measurement group_id="O2" value="-59.06" spread="158.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=110,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.02" spread="140.47"/>
                    <measurement group_id="O2" value="-65.99" spread="163.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 (n=110,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.25" spread="146.42"/>
                    <measurement group_id="O2" value="-56.59" spread="184.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=110,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.15" spread="136.85"/>
                    <measurement group_id="O2" value="-58.22" spread="163.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=110,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.28" spread="142.36"/>
                    <measurement group_id="O2" value="-44.48" spread="165.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=110,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.14" spread="137.69"/>
                    <measurement group_id="O2" value="-49.15" spread="202.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Subject-Reported Total Nap Time at Various Study Time Points</title>
        <description>The total time (minutes) spent napping per week for subjects who napped during the baseline period. Mean values are reported at baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the double-blind phase(average of weeks 3,6,9,12 values).</description>
        <time_frame>Weeks 0,3,6,9,12,14,16</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment and who napped at baseline are included. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Subject-Reported Total Nap Time at Various Study Time Points</title>
          <description>The total time (minutes) spent napping per week for subjects who napped during the baseline period. Mean values are reported at baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the double-blind phase(average of weeks 3,6,9,12 values).</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment and who napped at baseline are included. Last Observation Carried Forward.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (n=111,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189.31" spread="262.08"/>
                    <measurement group_id="O2" value="171.62" spread="237.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n=110,92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169.24" spread="253.66"/>
                    <measurement group_id="O2" value="114.43" spread="151.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=110,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150.88" spread="226.90"/>
                    <measurement group_id="O2" value="106.99" spread="133.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 (n=110,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150.65" spread="234.11"/>
                    <measurement group_id="O2" value="116.39" spread="156.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=110,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.75" spread="256.87"/>
                    <measurement group_id="O2" value="114.76" spread="149.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 3,6,9,12 (double blind average)(n=110,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154.88" spread="237.82"/>
                    <measurement group_id="O2" value="112.92" spread="135.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=110,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.61" spread="274.13"/>
                    <measurement group_id="O2" value="128.50" spread="173.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=110,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152.76" spread="246.50"/>
                    <measurement group_id="O2" value="123.83" spread="173.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Subject-Reported Total Nap Time Per Week as a Percent of Total Asleep Time Averaged Over the 12 Week Double Blind Study Period</title>
        <description>Change from baseline in the total time spent napping per week stated as a percentage of the total time asleep for subjects who napped during the baseline period. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</description>
        <time_frame>Baseline (week 0), Day 1 (post first dose) - week 12</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment and who napped at baseline are included. Last Observation Carried Forward. Number of participants in each arm 194, 194.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Subject-Reported Total Nap Time Per Week as a Percent of Total Asleep Time Averaged Over the 12 Week Double Blind Study Period</title>
          <description>Change from baseline in the total time spent napping per week stated as a percentage of the total time asleep for subjects who napped during the baseline period. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment and who napped at baseline are included. Last Observation Carried Forward. Number of participants in each arm 194, 194.</population>
          <units>percentage of total asleep time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.44" spread="8.29"/>
                    <measurement group_id="O2" value="-2.98" spread="5.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1182</p_value>
            <p_value_desc>Multiple comparisons not applied due to only two treatments in the study.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Subject-Reported Total Nap Time Stated as a Percentage of the Total Asleep Time at Various Study Time Points</title>
        <description>Change from baseline in the total time spent napping per week stated as a percentage of the total time asleep for subjects who napped during the baseline period. The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
        <time_frame>Baseline (week 0), Weeks 3,6,9,12,14,16</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment and who napped at baseline are included. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Subject-Reported Total Nap Time Stated as a Percentage of the Total Asleep Time at Various Study Time Points</title>
          <description>Change from baseline in the total time spent napping per week stated as a percentage of the total time asleep for subjects who napped during the baseline period. The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment and who napped at baseline are included. Last Observation Carried Forward.</population>
          <units>percentage of total asleep time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 3 (n=110,92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.78" spread="7.00"/>
                    <measurement group_id="O2" value="-2.77" spread="5.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=110,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.52" spread="9.09"/>
                    <measurement group_id="O2" value="-3.16" spread="5.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 (n=110,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.72" spread="9.26"/>
                    <measurement group_id="O2" value="-2.94" spread="6.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=110,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.76" spread="8.98"/>
                    <measurement group_id="O2" value="-3.04" spread="5.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=110,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.31" spread="9.22"/>
                    <measurement group_id="O2" value="-2.14" spread="5.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=110,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.55" spread="8.62"/>
                    <measurement group_id="O2" value="-2.38" spread="6.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Subject-Reported Total Nap Time Per Week Stated as a Percentage of the Total Asleep Time at Various Study Time Points</title>
        <description>Total time spent napping per week stated as a percentage of total time asleep for subjects who napped during baseline period. Mean values reported: baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week14), non-drug treatment follow-up(week 16), &amp; average for double-blind phase(average of weeks 3,6,9,12 values).</description>
        <time_frame>Weeks 0,3,6,9,12,14,16</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment and who napped at baseline are included. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Subject-Reported Total Nap Time Per Week Stated as a Percentage of the Total Asleep Time at Various Study Time Points</title>
          <description>Total time spent napping per week stated as a percentage of total time asleep for subjects who napped during baseline period. Mean values reported: baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week14), non-drug treatment follow-up(week 16), &amp; average for double-blind phase(average of weeks 3,6,9,12 values).</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment and who napped at baseline are included. Last Observation Carried Forward.</population>
          <units>percentage of total asleep time</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (n=111,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.05" spread="13.89"/>
                    <measurement group_id="O2" value="7.02" spread="8.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n=110,92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.35" spread="11.94"/>
                    <measurement group_id="O2" value="4.33" spread="5.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=110,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.61" spread="11.73"/>
                    <measurement group_id="O2" value="3.91" spread="4.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 (n=110,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.41" spread="11.04"/>
                    <measurement group_id="O2" value="4.13" spread="5.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=110,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.37" spread="11.77"/>
                    <measurement group_id="O2" value="4.04" spread="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 3,6,9,12 (double blind average)(n=110,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.68" spread="11.37"/>
                    <measurement group_id="O2" value="4.09" spread="4.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=110,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.82" spread="11.17"/>
                    <measurement group_id="O2" value="4.93" spread="6.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=110,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.57" spread="11.00"/>
                    <measurement group_id="O2" value="4.69" spread="6.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Total Sleep Time Measured by Actigraphy Averaged Over the 12 Week Double Blind Study Period</title>
        <description>Participants who wore an actigraph wrist monitor, which monitors rest and activity cycles are included; the resultant data had total sleep time calculated by a Central Reader. The change is calculated as the average over the double blind period (average of post-dose values from weeks 1,4,7,12) minus the baseline value.</description>
        <time_frame>Baseline (week 0), Day 1 (post first dose) - week 12</time_frame>
        <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.Actigraphy population N=72,69.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Total Sleep Time Measured by Actigraphy Averaged Over the 12 Week Double Blind Study Period</title>
          <description>Participants who wore an actigraph wrist monitor, which monitors rest and activity cycles are included; the resultant data had total sleep time calculated by a Central Reader. The change is calculated as the average over the double blind period (average of post-dose values from weeks 1,4,7,12) minus the baseline value.</description>
          <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.Actigraphy population N=72,69.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.40" spread="38.14"/>
                    <measurement group_id="O2" value="17.96" spread="34.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3010</p_value>
            <p_value_desc>Multiple comparisons not applied due to only two treatments in the study.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and site type as fixed effects and the baseline as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Total Sleep Time Measured by Actigraphy at Various Study Time Points</title>
        <description>Change from baseline in total sleep time for the subset population who wore an actigraph wrist monitor. The actigraph monitors rest and activity cycles; the resultant data had sleep parameters calculated by a Central Reader. The change is calculated as time point value minus the baseline value.</description>
        <time_frame>Baseline (week 0), Weeks 1,4,7,12,13,15</time_frame>
        <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Total Sleep Time Measured by Actigraphy at Various Study Time Points</title>
          <description>Change from baseline in total sleep time for the subset population who wore an actigraph wrist monitor. The actigraph monitors rest and activity cycles; the resultant data had sleep parameters calculated by a Central Reader. The change is calculated as time point value minus the baseline value.</description>
          <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n=60,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.72" spread="54.09"/>
                    <measurement group_id="O2" value="14.97" spread="36.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=61,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.21" spread="39.97"/>
                    <measurement group_id="O2" value="16.89" spread="41.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7 (n=62,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.72" spread="57.85"/>
                    <measurement group_id="O2" value="22.12" spread="41.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=62,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.93" spread="44.73"/>
                    <measurement group_id="O2" value="18.08" spread="52.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 (n=62,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.36" spread="51.72"/>
                    <measurement group_id="O2" value="-0.60" spread="56.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15 (n=62,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.82" spread="43.48"/>
                    <measurement group_id="O2" value="4.06" spread="47.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Total Sleep Time Measured by Actigraphy at Various Study Time Points</title>
        <description>Total sleep time for subset who wore actigraph wrist monitor which monitors rest and activity cycles, sleep parameters calculated by Central Reader. Mean values reported:baseline(week0), double-blind(weeks1,4,7,12), single-blind follow-up(week13), non-drug follow-up(week15) &amp; average for double-blind(average of weeks1,4,7,12 values).</description>
        <time_frame>Weeks 0,1,4,7,12,13,15</time_frame>
        <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Total Sleep Time Measured by Actigraphy at Various Study Time Points</title>
          <description>Total sleep time for subset who wore actigraph wrist monitor which monitors rest and activity cycles, sleep parameters calculated by Central Reader. Mean values reported:baseline(week0), double-blind(weeks1,4,7,12), single-blind follow-up(week13), non-drug follow-up(week15) &amp; average for double-blind(average of weeks1,4,7,12 values).</description>
          <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (n=64,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="351.06" spread="86.05"/>
                    <measurement group_id="O2" value="367.95" spread="60.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (n=64,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="354.11" spread="94.76"/>
                    <measurement group_id="O2" value="381.52" spread="73.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=67,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="366.69" spread="78.34"/>
                    <measurement group_id="O2" value="382.39" spread="69.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7 (n=68,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="368.58" spread="86.48"/>
                    <measurement group_id="O2" value="386.96" spread="63.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=68,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="368.70" spread="83.39"/>
                    <measurement group_id="O2" value="382.04" spread="69.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 1,4,7,12 (double blind average)(n=68,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="365.13" spread="79.31"/>
                    <measurement group_id="O2" value="383.30" spread="63.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 (n=68,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="366.47" spread="81.33"/>
                    <measurement group_id="O2" value="364.87" spread="74.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15 (n=68,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="365.73" spread="74.47"/>
                    <measurement group_id="O2" value="369.23" spread="64.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Sleep Latency Measured Using Actigraphy Averaged Over the 12 Week Double Blind Study Period</title>
        <description>Sleep latency is the time it takes to fall asleep. Participants who wore an actigraph wrist monitor to record rest and activity cycles are included; a Central Reader calculated sleep parameters. The change is calculated as the average over the double blind period (average of post-dose values from weeks 1,4,7,12) minus the baseline value.</description>
        <time_frame>Baseline (week 0), Day 1 (post first dose) - week 12</time_frame>
        <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.Actigraphy population N=72,69.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Sleep Latency Measured Using Actigraphy Averaged Over the 12 Week Double Blind Study Period</title>
          <description>Sleep latency is the time it takes to fall asleep. Participants who wore an actigraph wrist monitor to record rest and activity cycles are included; a Central Reader calculated sleep parameters. The change is calculated as the average over the double blind period (average of post-dose values from weeks 1,4,7,12) minus the baseline value.</description>
          <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.Actigraphy population N=72,69.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="40.75"/>
                    <measurement group_id="O2" value="1.47" spread="26.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7800</p_value>
            <p_value_desc>Multiple comparisons not applied due to only two treatments in the study.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and site type as fixed effects and the baseline as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Sleep Latency Measured Using Actigraphy at Various Study Time Points</title>
        <description>Sleep latency is a measurement of the time it takes to fall asleep. Participants who wore an actigraph wrist monitor to record rest and activity cycles are included; a Central Reader calculated sleep parameters. The change is calculated as time point value minus the baseline value.</description>
        <time_frame>Baseline (week 0), Weeks 1,4,7,12,13,15</time_frame>
        <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Sleep Latency Measured Using Actigraphy at Various Study Time Points</title>
          <description>Sleep latency is a measurement of the time it takes to fall asleep. Participants who wore an actigraph wrist monitor to record rest and activity cycles are included; a Central Reader calculated sleep parameters. The change is calculated as time point value minus the baseline value.</description>
          <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n=60,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.06" spread="74.76"/>
                    <measurement group_id="O2" value="-0.25" spread="18.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=61,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.16" spread="44.61"/>
                    <measurement group_id="O2" value="-1.48" spread="27.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7 (n=62,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="52.95"/>
                    <measurement group_id="O2" value="-1.62" spread="26.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=62,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.92" spread="36.22"/>
                    <measurement group_id="O2" value="9.34" spread="57.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 (n=62,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" spread="59.32"/>
                    <measurement group_id="O2" value="16.13" spread="66.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15 (n=62,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.66" spread="39.21"/>
                    <measurement group_id="O2" value="6.44" spread="36.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Sleep Latency Values Measured Using Actigraphy at Various Study Time Points.</title>
        <description>Sleep latency:measurement of time to fall asleep. Values are for subset who wore an actigraph wrist monitor which monitors rest and activity cycles; sleep parameters calculated by Central Reader.</description>
        <time_frame>Weeks 0,1,4,7,12,13,15</time_frame>
        <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. Mean values reported:baseline(week0), double-blind (weeks 1,4,7,12), single-blind follow-up(week13), non-drug treatment follow-up(week15) &amp; average for double-blind (average of weeks 1,4,7,12 values). Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Sleep Latency Values Measured Using Actigraphy at Various Study Time Points.</title>
          <description>Sleep latency:measurement of time to fall asleep. Values are for subset who wore an actigraph wrist monitor which monitors rest and activity cycles; sleep parameters calculated by Central Reader.</description>
          <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. Mean values reported:baseline(week0), double-blind (weeks 1,4,7,12), single-blind follow-up(week13), non-drug treatment follow-up(week15) &amp; average for double-blind (average of weeks 1,4,7,12 values). Last Observation Carried Forward.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (n=64,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.34" spread="65.06"/>
                    <measurement group_id="O2" value="23.89" spread="24.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (n=64,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.74" spread="78.14"/>
                    <measurement group_id="O2" value="26.72" spread="36.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=67,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.55" spread="35.46"/>
                    <measurement group_id="O2" value="26.62" spread="43.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7 (n=68,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.06" spread="42.82"/>
                    <measurement group_id="O2" value="26.89" spread="33.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=68,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.89" spread="38.78"/>
                    <measurement group_id="O2" value="36.93" spread="57.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 1,4,7,12 (double blind average)(n=68,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.20" spread="36.89"/>
                    <measurement group_id="O2" value="29.22" spread="35.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 (n=68,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.40" spread="41.05"/>
                    <measurement group_id="O2" value="43.06" spread="64.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15 (n=68,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.80" spread="37.75"/>
                    <measurement group_id="O2" value="34.35" spread="40.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Wake Time After Sleep Onset (WASO) Measured by Actigraphy Averaged Over the 12 Week Double Blind Study Period</title>
        <description>Wake time after sleep onset is the time spent awake from sleep onset to final awakening. Change is calculated as average over double blind period (average of post-dose values from weeks 1,4,7,12) minus the baseline value.</description>
        <time_frame>Baseline (week 0), Day 1 (post first dose) - week 12</time_frame>
        <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.Actigraphy population N=72,69.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Wake Time After Sleep Onset (WASO) Measured by Actigraphy Averaged Over the 12 Week Double Blind Study Period</title>
          <description>Wake time after sleep onset is the time spent awake from sleep onset to final awakening. Change is calculated as average over double blind period (average of post-dose values from weeks 1,4,7,12) minus the baseline value.</description>
          <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.Actigraphy population N=72,69.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.50" spread="19.54"/>
                    <measurement group_id="O2" value="-4.24" spread="22.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0803</p_value>
            <p_value_desc>Multiple comparisons not applied due to only two treatments in the study.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and site type as fixed effects and the baseline as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Wake Time After Sleep Onset Measured Using Actigraphy at Various Study Time Points</title>
        <description>Wake time after sleep onset is the time spent awake from sleep onset to final awakening. Participants who wore an actigraph wrist monitor to record rest and activity cycles are included; a Central Reader calculated sleep parameters. The change is calculated as time point value minus the baseline value.</description>
        <time_frame>Baseline (week 0), Weeks 1,4,7,12,13,15</time_frame>
        <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Wake Time After Sleep Onset Measured Using Actigraphy at Various Study Time Points</title>
          <description>Wake time after sleep onset is the time spent awake from sleep onset to final awakening. Participants who wore an actigraph wrist monitor to record rest and activity cycles are included; a Central Reader calculated sleep parameters. The change is calculated as time point value minus the baseline value.</description>
          <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n=59,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.17" spread="16.23"/>
                    <measurement group_id="O2" value="-6.59" spread="23.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=61,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.67" spread="23.36"/>
                    <measurement group_id="O2" value="-3.88" spread="26.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7 (n=62,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.57" spread="30.27"/>
                    <measurement group_id="O2" value="-4.19" spread="25.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=62,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.24" spread="17.90"/>
                    <measurement group_id="O2" value="-2.54" spread="24.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 (n=62,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.98" spread="22.35"/>
                    <measurement group_id="O2" value="0.68" spread="23.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15 (n=62,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.74" spread="25.70"/>
                    <measurement group_id="O2" value="-0.27" spread="24.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Values for Wake Time After Sleep Onset Measured Using Actigraphy at Various Study Time Points</title>
        <description>Wake time after sleep onset is time spent awake from sleep onset to final awakening. Mean values reported: baseline(week 0), double-blind phase(weeks 1,4,7,12), single-blind follow-up(week 13), non-drug treatment follow-up(week 15) &amp; average for double-blind phase(average of weeks 1,4,7,12 values).</description>
        <time_frame>weeks 0,1,4,7,12,13,15</time_frame>
        <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Values for Wake Time After Sleep Onset Measured Using Actigraphy at Various Study Time Points</title>
          <description>Wake time after sleep onset is time spent awake from sleep onset to final awakening. Mean values reported: baseline(week 0), double-blind phase(weeks 1,4,7,12), single-blind follow-up(week 13), non-drug treatment follow-up(week 15) &amp; average for double-blind phase(average of weeks 1,4,7,12 values).</description>
          <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (n=64,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.27" spread="29.51"/>
                    <measurement group_id="O2" value="63.75" spread="29.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (n=63,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.53" spread="31.09"/>
                    <measurement group_id="O2" value="55.39" spread="22.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=67,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.16" spread="32.11"/>
                    <measurement group_id="O2" value="58.86" spread="24.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7 (n=68,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.81" spread="35.11"/>
                    <measurement group_id="O2" value="58.09" spread="22.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=68,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.41" spread="30.09"/>
                    <measurement group_id="O2" value="60.22" spread="23.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 1,4,7,12 (double blind average)(n=68,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.69" spread="29.90"/>
                    <measurement group_id="O2" value="58.21" spread="20.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 (n=68,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.09" spread="31.39"/>
                    <measurement group_id="O2" value="63.01" spread="27.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15 (n=68,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.07" spread="37.40"/>
                    <measurement group_id="O2" value="62.27" spread="25.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Number of Awakenings Using Actigraphy Averaged Over the 12 Week Double Blind Study Period</title>
        <description>Number of awakenings refers to the number of times a subject awakens between first sleep onset to final awakening. Change is calculated as average over double blind period (average of post-dose values from weeks 1,4,7,12) minus the baseline value.</description>
        <time_frame>Baseline (week 0), Day 1 (post first dose) - week 12</time_frame>
        <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.Actigraphy population N=72,69.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Number of Awakenings Using Actigraphy Averaged Over the 12 Week Double Blind Study Period</title>
          <description>Number of awakenings refers to the number of times a subject awakens between first sleep onset to final awakening. Change is calculated as average over double blind period (average of post-dose values from weeks 1,4,7,12) minus the baseline value.</description>
          <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.Actigraphy population N=72,69.</population>
          <units>number of awakenings</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" spread="3.65"/>
                    <measurement group_id="O2" value="-0.18" spread="4.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2643</p_value>
            <p_value_desc>Multiple comparisons not applied due to only two treatments in the study.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and site type as fixed effects and the baseline as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of Awakenings Measured Using Actigraphy at Various Study Time Points.</title>
        <description>Number of awakenings refers to the number of times a subject awakens between first sleep onset to final awakening. Participants who wore an actigraph wrist monitor to record rest and activity cycles are included; a Central Reader calculated sleep parameters. The change is calculated as time point value minus the baseline value.</description>
        <time_frame>Baseline (week 0), Weeks 1,4,7,12,13,15</time_frame>
        <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Awakenings Measured Using Actigraphy at Various Study Time Points.</title>
          <description>Number of awakenings refers to the number of times a subject awakens between first sleep onset to final awakening. Participants who wore an actigraph wrist monitor to record rest and activity cycles are included; a Central Reader calculated sleep parameters. The change is calculated as time point value minus the baseline value.</description>
          <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.</population>
          <units>number of awakenings</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n=59,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="3.09"/>
                    <measurement group_id="O2" value="-0.54" spread="4.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=61,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="4.62"/>
                    <measurement group_id="O2" value="0.04" spread="5.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7 (n=62,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" spread="4.73"/>
                    <measurement group_id="O2" value="-0.21" spread="5.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=62,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" spread="4.60"/>
                    <measurement group_id="O2" value="-0.10" spread="4.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 (n=62,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" spread="4.69"/>
                    <measurement group_id="O2" value="0.01" spread="4.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15 (n=62,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" spread="4.35"/>
                    <measurement group_id="O2" value="-0.13" spread="5.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Awakenings Measured Using Actigraphy at Various Study Time Points</title>
        <description>Number of awakenings refers to the number of times a subject awakens between first sleep onset to final awakening. Mean values are reported at baseline(week 0), double-blind phase(weeks 1,4,7,12), single-blind follow-up(week 13), non-drug treatment follow-up(week 15), and the average for the double-blind phase(average of weeks 1,4,7,12 values).</description>
        <time_frame>Weeks 0,1,4,7,12,13,15</time_frame>
        <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Awakenings Measured Using Actigraphy at Various Study Time Points</title>
          <description>Number of awakenings refers to the number of times a subject awakens between first sleep onset to final awakening. Mean values are reported at baseline(week 0), double-blind phase(weeks 1,4,7,12), single-blind follow-up(week 13), non-drug treatment follow-up(week 15), and the average for the double-blind phase(average of weeks 1,4,7,12 values).</description>
          <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.</population>
          <units>number of awakenings</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (n=64,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.49" spread="7.53"/>
                    <measurement group_id="O2" value="22.84" spread="6.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (n=63,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.42" spread="7.17"/>
                    <measurement group_id="O2" value="21.86" spread="5.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=67,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.28" spread="7.30"/>
                    <measurement group_id="O2" value="22.51" spread="6.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7 (n=68,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.52" spread="7.93"/>
                    <measurement group_id="O2" value="22.19" spread="6.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=68,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.36" spread="7.76"/>
                    <measurement group_id="O2" value="22.37" spread="6.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 1,4,7,12 (double blind average)(n=68,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.40" spread="7.15"/>
                    <measurement group_id="O2" value="22.27" spread="5.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 (n=68,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.55" spread="7.57"/>
                    <measurement group_id="O2" value="22.48" spread="7.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15 (n=68,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.87" spread="7.71"/>
                    <measurement group_id="O2" value="22.38" spread="5.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Number of Naps Per Week Measured Using Actigraphy Averaged Over the 12 Week Double Blind Study Period</title>
        <description>Change from baseline in the number of naps per week for subjects who napped during the baseline period. Change is calculated as the average over the double blind period (average of post-dose values from weeks 1,4,7,12) minus the baseline value.</description>
        <time_frame>Baseline (week 0), Day 1 (post first dose) - week 12</time_frame>
        <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.Actigraphy population N=72,69.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Number of Naps Per Week Measured Using Actigraphy Averaged Over the 12 Week Double Blind Study Period</title>
          <description>Change from baseline in the number of naps per week for subjects who napped during the baseline period. Change is calculated as the average over the double blind period (average of post-dose values from weeks 1,4,7,12) minus the baseline value.</description>
          <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.Actigraphy population N=72,69.</population>
          <units>number of naps</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" spread="9.06"/>
                    <measurement group_id="O2" value="-2.67" spread="12.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0765</p_value>
            <p_value_desc>Multiple comparisons not applied due to only two treatments in the study.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and site type as fixed effects and the baseline as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of Naps Per Week Measured Using Actigraphy at Various Study Time Points</title>
        <description>Change from baseline in the number of naps per week for subjects who napped during the baseline period. Participants who wore an actigraph wrist monitor to record rest and activity cycles are included; a Central Reader calculated sleep parameters. The change is calculated as time point value minus the baseline value.</description>
        <time_frame>Baseline (week 0), Weeks 1,4,7,12,13,15</time_frame>
        <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Naps Per Week Measured Using Actigraphy at Various Study Time Points</title>
          <description>Change from baseline in the number of naps per week for subjects who napped during the baseline period. Participants who wore an actigraph wrist monitor to record rest and activity cycles are included; a Central Reader calculated sleep parameters. The change is calculated as time point value minus the baseline value.</description>
          <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.</population>
          <units>number of naps</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n=57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="9.15"/>
                    <measurement group_id="O2" value="-0.62" spread="12.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=57,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" spread="11.73"/>
                    <measurement group_id="O2" value="-3.43" spread="13.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7 (n=58,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.68" spread="10.63"/>
                    <measurement group_id="O2" value="-2.83" spread="16.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=58,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.86" spread="9.83"/>
                    <measurement group_id="O2" value="-3.47" spread="15.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 (n=58,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.73" spread="10.54"/>
                    <measurement group_id="O2" value="-4.58" spread="13.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15 (n=58,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.41" spread="11.22"/>
                    <measurement group_id="O2" value="-0.64" spread="12.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Naps Per Week Measured Using Actigraphy at Various Study Time Points</title>
        <description>The number of naps per week for subjects who napped during the baseline period. Mean values are reported at baseline(week 0), double-blind phase(weeks 1,4,7,12), single-blind follow-up(week 13), non-drug treatment follow-up(week 15), and the average for the double-blind phase(average of weeks 1,4,7,12 values).</description>
        <time_frame>Week 0,1,4,7,12,13,15</time_frame>
        <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Naps Per Week Measured Using Actigraphy at Various Study Time Points</title>
          <description>The number of naps per week for subjects who napped during the baseline period. Mean values are reported at baseline(week 0), double-blind phase(weeks 1,4,7,12), single-blind follow-up(week 13), non-drug treatment follow-up(week 15), and the average for the double-blind phase(average of weeks 1,4,7,12 values).</description>
          <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.</population>
          <units>number of naps</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (n=62,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.52" spread="15.63"/>
                    <measurement group_id="O2" value="22.33" spread="15.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (n=57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.94" spread="14.99"/>
                    <measurement group_id="O2" value="21.69" spread="15.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=57,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.63" spread="15.38"/>
                    <measurement group_id="O2" value="18.90" spread="13.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7 (n=58,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.07" spread="14.93"/>
                    <measurement group_id="O2" value="19.50" spread="15.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=58,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.25" spread="14.29"/>
                    <measurement group_id="O2" value="18.86" spread="15.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 1,4,7,12 (double blind average)(n=58,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.01" spread="13.90"/>
                    <measurement group_id="O2" value="19.66" spread="12.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 (n=58,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.12" spread="15.97"/>
                    <measurement group_id="O2" value="17.75" spread="12.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15 (n=58,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.80" spread="15.03"/>
                    <measurement group_id="O2" value="21.69" spread="14.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline Total Nap Time Per Week Measured by Actigraphy Averaged Over the 12 Week Double Blind Study Period</title>
        <description>Change from baseline in the total nap time per week for subjects who napped during the baseline period. Change is calculated as the average over the double blind period (average of post-dose values from weeks 1,4,7,12) minus the baseline value.</description>
        <time_frame>Baseline (week 0), Day 1 (post first dose) - week 12</time_frame>
        <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.Actigraphy population N=72,69.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline Total Nap Time Per Week Measured by Actigraphy Averaged Over the 12 Week Double Blind Study Period</title>
          <description>Change from baseline in the total nap time per week for subjects who napped during the baseline period. Change is calculated as the average over the double blind period (average of post-dose values from weeks 1,4,7,12) minus the baseline value.</description>
          <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.Actigraphy population N=72,69.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.26" spread="196.66"/>
                    <measurement group_id="O2" value="-40.91" spread="307.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2967</p_value>
            <p_value_desc>Multiple comparisons not applied due to only two treatments in the study.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and site type as fixed effects and the baseline as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Total Nap Time Per Week Measured by Actigraphy at Various Study Time Points</title>
        <description>Change from baseline in the total nap time per week for subjects who napped during the baseline period. Participants who wore an actigraph wrist monitor to record rest and activity cycles are included; a Central Reader calculated sleep parameters. The change is calculated as time point value minus the baseline value.</description>
        <time_frame>Baseline (week 0), Weeks 1,4,7,12,13,15</time_frame>
        <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Total Nap Time Per Week Measured by Actigraphy at Various Study Time Points</title>
          <description>Change from baseline in the total nap time per week for subjects who napped during the baseline period. Participants who wore an actigraph wrist monitor to record rest and activity cycles are included; a Central Reader calculated sleep parameters. The change is calculated as time point value minus the baseline value.</description>
          <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n=57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.37" spread="184.85"/>
                    <measurement group_id="O2" value="6.56" spread="285.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=57,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.37" spread="252.54"/>
                    <measurement group_id="O2" value="-56.87" spread="336.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7 (n=58,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.03" spread="220.20"/>
                    <measurement group_id="O2" value="-31.85" spread="428.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=58,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.86" spread="229.45"/>
                    <measurement group_id="O2" value="-73.67" spread="338.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 (n=58,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.84" spread="275.99"/>
                    <measurement group_id="O2" value="-87.50" spread="291.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15 (n=58,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.28" spread="235.24"/>
                    <measurement group_id="O2" value="-1.99" spread="240.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Total Nap Time Per Week Measured by Actigraphy at Various Study Time Points.</title>
        <description>The total nap time per week for subjects who napped during the baseline period. Mean values are reported at baseline(week 0), double-blind phase(weeks 1,4,7,12), single-blind follow-up(week 13), non-drug treatment follow-up(week 15), and the average for the double-blind phase(average of weeks 1,4,7,12 values).</description>
        <time_frame>Week 0,1,4,7,12,13,15</time_frame>
        <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Total Nap Time Per Week Measured by Actigraphy at Various Study Time Points.</title>
          <description>The total nap time per week for subjects who napped during the baseline period. Mean values are reported at baseline(week 0), double-blind phase(weeks 1,4,7,12), single-blind follow-up(week 13), non-drug treatment follow-up(week 15), and the average for the double-blind phase(average of weeks 1,4,7,12 values).</description>
          <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (n=62,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="418.49" spread="368.31"/>
                    <measurement group_id="O2" value="438.02" spread="325.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (n=57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="399.19" spread="298.18"/>
                    <measurement group_id="O2" value="445.84" spread="358.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=57,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="403.18" spread="328.59"/>
                    <measurement group_id="O2" value="381.15" spread="335.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7 (n=58,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="414.68" spread="315.20"/>
                    <measurement group_id="O2" value="406.16" spread="387.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=58,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="430.50" spread="313.11"/>
                    <measurement group_id="O2" value="364.34" spread="313.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 1,4,7,12 (double blind average)(n=58,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="412.91" spread="292.66"/>
                    <measurement group_id="O2" value="397.11" spread="305.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 (n=58,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="456.48" spread="352.10"/>
                    <measurement group_id="O2" value="350.52" spread="262.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15 (n=58,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="452.93" spread="310.68"/>
                    <measurement group_id="O2" value="436.03" spread="297.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Total Nap Time Per Week as a Percentage of Total Asleep Time Measured by Actigraphy and Averaged Over the 12 Week Double Blind Study Period.</title>
        <description>Change from baseline in the total time spent napping per week as a percent of the total time asleep for subjects who napped during the baseline period. Change is calculated as the average over the double blind period (average of post-dose values from weeks 1,4,7,12) minus the baseline value.</description>
        <time_frame>Baseline (week 0), Day 1 (post first dose) - week 12</time_frame>
        <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.Actigraphy population N=72,69.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Total Nap Time Per Week as a Percentage of Total Asleep Time Measured by Actigraphy and Averaged Over the 12 Week Double Blind Study Period.</title>
          <description>Change from baseline in the total time spent napping per week as a percent of the total time asleep for subjects who napped during the baseline period. Change is calculated as the average over the double blind period (average of post-dose values from weeks 1,4,7,12) minus the baseline value.</description>
          <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.Actigraphy population N=72,69.</population>
          <units>percentage of total asleep time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="7.84"/>
                    <measurement group_id="O2" value="-1.75" spread="8.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0634</p_value>
            <p_value_desc>Multiple comparisons not applied due to only two treatments in the study.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and site type as fixed effects and the baseline as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Total Nap Time Per Week as a Percentage of Total Asleep Time as Measured by Actigraphy at Various Study Time Points</title>
        <description>Change from baseline in total time spent napping per week as a percent of total time asleep for subjects who napped during the baseline period. Change is calculated as time point value minus the baseline value.</description>
        <time_frame>Baseline (week 0), Weeks 1,4,7,12,13,15</time_frame>
        <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Total Nap Time Per Week as a Percentage of Total Asleep Time as Measured by Actigraphy at Various Study Time Points</title>
          <description>Change from baseline in total time spent napping per week as a percent of total time asleep for subjects who napped during the baseline period. Change is calculated as time point value minus the baseline value.</description>
          <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.</population>
          <units>percentage of total asleep time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n=57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" spread="13.89"/>
                    <measurement group_id="O2" value="-0.17" spread="7.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=57,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.56" spread="8.64"/>
                    <measurement group_id="O2" value="-2.14" spread="9.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7 (n=58,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="9.21"/>
                    <measurement group_id="O2" value="-1.75" spread="11.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=58,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="7.76"/>
                    <measurement group_id="O2" value="-2.70" spread="9.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 (n=58,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" spread="7.96"/>
                    <measurement group_id="O2" value="-2.63" spread="8.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15 (n=58,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" spread="8.11"/>
                    <measurement group_id="O2" value="-0.04" spread="7.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Total Nap Time Per Week as a Percentage of Total Asleep Time Measured Using Actigraphy at Various Study Time Points</title>
        <description>The total time spent napping per week as a percent of the total time asleep for subjects who napped during the baseline period. Mean values reported: baseline(week 0), double-blind phase(weeks 1,4,7,12), single-blind follow-up(week 13), non-drug treatment follow-up(week 15) &amp; average for double-blind phase(average of weeks 1,4,7,12 values).</description>
        <time_frame>Week 0,1,4,7,12,13,15</time_frame>
        <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Total Nap Time Per Week as a Percentage of Total Asleep Time Measured Using Actigraphy at Various Study Time Points</title>
          <description>The total time spent napping per week as a percent of the total time asleep for subjects who napped during the baseline period. Mean values reported: baseline(week 0), double-blind phase(weeks 1,4,7,12), single-blind follow-up(week 13), non-drug treatment follow-up(week 15) &amp; average for double-blind phase(average of weeks 1,4,7,12 values).</description>
          <population>The subset population wore an actigraph wrist monitor device every day between Weeks -1 and 16. A total of 17 weeks of actigraphy data was collected but only 7 weeks (Weeks 0,1,4,7,12,13,15) of actigraphy data was overread by a Central Reader and had sleep parameters calculated. Last Observation Carried Forward.</population>
          <units>percentage of total asleep time</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (n=62,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.12" spread="15.32"/>
                    <measurement group_id="O2" value="14.05" spread="9.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (n=57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.29" spread="17.55"/>
                    <measurement group_id="O2" value="13.89" spread="10.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=57,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.35" spread="13.63"/>
                    <measurement group_id="O2" value="11.92" spread="9.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7 (n=58,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.90" spread="12.97"/>
                    <measurement group_id="O2" value="12.30" spread="10.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=58,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.18" spread="13.23"/>
                    <measurement group_id="O2" value="11.36" spread="9.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 1,4,7,12 (double blind average)(n=58,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.16" spread="12.87"/>
                    <measurement group_id="O2" value="12.30" spread="8.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 (n=58,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.66" spread="13.84"/>
                    <measurement group_id="O2" value="11.43" spread="8.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15 (n=58,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.66" spread="12.42"/>
                    <measurement group_id="O2" value="14.01" spread="8.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Insomnia Severity Index Total Score Averaged Over the 12 Week Double Blind Study Period</title>
        <description>Change from baseline in the Insomnia Severity Index Total Score which ranges from 0-28. Lower scores represent better sleep. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</description>
        <time_frame>Baseline (week 0), Day 1 (post first dose) - week 12</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward. Number of participants in each arm 194, 194.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Insomnia Severity Index Total Score Averaged Over the 12 Week Double Blind Study Period</title>
          <description>Change from baseline in the Insomnia Severity Index Total Score which ranges from 0-28. Lower scores represent better sleep. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward. Number of participants in each arm 194, 194.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.42" spread="4.38"/>
                    <measurement group_id="O2" value="-5.67" spread="5.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiple comparisons not applied due to only two treatments in the study.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and site type as fixed effects and the baseline as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Insomnia Severity Index Total Score at Various Study Time Points</title>
        <description>Change from baseline in the Insomnia Severity Index Total Score which ranges from 0-28. Lower scores represent better sleep. The change is calculated as time point value minus the baseline value.</description>
        <time_frame>Baseline (week 0), Weeks 3,6,9,12,14,16</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Insomnia Severity Index Total Score at Various Study Time Points</title>
          <description>Change from baseline in the Insomnia Severity Index Total Score which ranges from 0-28. Lower scores represent better sleep. The change is calculated as time point value minus the baseline value.</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 3 (n=179,181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.74" spread="4.51"/>
                    <measurement group_id="O2" value="-4.94" spread="5.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=180,181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.35" spread="4.89"/>
                    <measurement group_id="O2" value="-5.67" spread="5.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 (n=180,182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.55" spread="5.10"/>
                    <measurement group_id="O2" value="-5.89" spread="5.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=180,182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.05" spread="5.15"/>
                    <measurement group_id="O2" value="-6.18" spread="5.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=181,182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.93" spread="5.25"/>
                    <measurement group_id="O2" value="-4.06" spread="5.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=181,182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.96" spread="5.16"/>
                    <measurement group_id="O2" value="-2.96" spread="5.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Insomnia Severity Index Total Scores at Various Study Time Points</title>
        <description>The Insomnia Severity Index Total Score ranges from 0-28. Lower scores represent better sleep. Mean values are reported at baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the double-blind phase(average of weeks 3,6,9,12 values).</description>
        <time_frame>Weeks 0,3,6,9,12,14,16</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Insomnia Severity Index Total Scores at Various Study Time Points</title>
          <description>The Insomnia Severity Index Total Score ranges from 0-28. Lower scores represent better sleep. Mean values are reported at baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the double-blind phase(average of weeks 3,6,9,12 values).</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (n=192,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.34" spread="4.18"/>
                    <measurement group_id="O2" value="16.12" spread="4.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n=180,183)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.52" spread="5.11"/>
                    <measurement group_id="O2" value="11.09" spread="5.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=181,184)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.87" spread="5.26"/>
                    <measurement group_id="O2" value="10.40" spread="5.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 (n=181,185)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.66" spread="5.58"/>
                    <measurement group_id="O2" value="10.12" spread="5.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=181,185)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.16" spread="5.51"/>
                    <measurement group_id="O2" value="9.84" spread="5.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 3,6,9,12 (double blind average)(n=181,185)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.80" spread="4.87"/>
                    <measurement group_id="O2" value="10.36" spread="5.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=182,185)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.30" spread="5.68"/>
                    <measurement group_id="O2" value="11.94" spread="5.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=182,185)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.28" spread="5.39"/>
                    <measurement group_id="O2" value="13.05" spread="5.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Physical Component Summary of the Short Form-36 Scale</title>
        <description>Physical component summary of Short Form-36 Scale measures subject's perception of their physical health, where the normal mean for general US population is 50.Scores above/below 50 represent better than/worse than the general US population. Higher scores represent better outcomes. Change is calculated as time point value minus baseline value.</description>
        <time_frame>Baseline (week 0), Weeks 6, 12, 16</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Physical Component Summary of the Short Form-36 Scale</title>
          <description>Physical component summary of Short Form-36 Scale measures subject's perception of their physical health, where the normal mean for general US population is 50.Scores above/below 50 represent better than/worse than the general US population. Higher scores represent better outcomes. Change is calculated as time point value minus baseline value.</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 6 (n=164,165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" spread="7.73"/>
                    <measurement group_id="O2" value="1.00" spread="7.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=165,166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" spread="7.60"/>
                    <measurement group_id="O2" value="1.01" spread="7.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=166,166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" spread="7.99"/>
                    <measurement group_id="O2" value="0.39" spread="6.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Physical Component Summary of the Short Form-36 Scale Scores.</title>
        <description>This scale measures subject's perception of their physical health, where the normal mean for general US population is 50.Scores above/below 50 represent better/worse than general US population. Change calculated as time point value minus baseline value: baseline(week0), double-blind (weeks 6,12)and non-drug treatment follow-up(week16).</description>
        <time_frame>Weeks 0,6,12,16</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Physical Component Summary of the Short Form-36 Scale Scores.</title>
          <description>This scale measures subject's perception of their physical health, where the normal mean for general US population is 50.Scores above/below 50 represent better/worse than general US population. Change calculated as time point value minus baseline value: baseline(week0), double-blind (weeks 6,12)and non-drug treatment follow-up(week16).</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (n=192,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.99" spread="10.67"/>
                    <measurement group_id="O2" value="45.39" spread="9.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=165,168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.06" spread="10.98"/>
                    <measurement group_id="O2" value="46.08" spread="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=166,169)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.38" spread="10.57"/>
                    <measurement group_id="O2" value="46.12" spread="9.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=167,169)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.70" spread="10.98"/>
                    <measurement group_id="O2" value="45.51" spread="9.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Mental Component Summary of the Short Form-36 Scale Scores</title>
        <description>Mental component summary of Short Form-36 Scale measures subject's perception of their physical health, where the normal mean for general US population is 50. Scores above/below 50 represent better than/worse than the general US population. Higher scores represent better outcomes. Change is calculated as time point value minus baseline value.</description>
        <time_frame>Baseline (week 0), Weeks 6,12,16</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Mental Component Summary of the Short Form-36 Scale Scores</title>
          <description>Mental component summary of Short Form-36 Scale measures subject's perception of their physical health, where the normal mean for general US population is 50. Scores above/below 50 represent better than/worse than the general US population. Higher scores represent better outcomes. Change is calculated as time point value minus baseline value.</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 6 (n=164,165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="7.45"/>
                    <measurement group_id="O2" value="0.96" spread="8.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=165,166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.94" spread="8.00"/>
                    <measurement group_id="O2" value="0.83" spread="8.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=166,166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.22" spread="8.94"/>
                    <measurement group_id="O2" value="0.20" spread="7.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Mental Component Summary of the Short Form-36 Scale Scores</title>
        <description>This scale measures subject's perception of their physical health, where normal mean for general US population is 50. Scores above/below 50 represent better/worse than general US population. Change calculated: time point value minus baseline value. Mean values: baseline(week0), double-blind phase(weeks 6,12)&amp; non-drug treatment follow-up(week 16).</description>
        <time_frame>Weeks 0,6,12,16</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Mental Component Summary of the Short Form-36 Scale Scores</title>
          <description>This scale measures subject's perception of their physical health, where normal mean for general US population is 50. Scores above/below 50 represent better/worse than general US population. Change calculated: time point value minus baseline value. Mean values: baseline(week0), double-blind phase(weeks 6,12)&amp; non-drug treatment follow-up(week 16).</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (n=192,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.69" spread="9.33"/>
                    <measurement group_id="O2" value="49.29" spread="10.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=165,168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.49" spread="10.03"/>
                    <measurement group_id="O2" value="49.96" spread="10.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=166,169)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.98" spread="10.19"/>
                    <measurement group_id="O2" value="49.86" spread="9.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=167,169)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.68" spread="10.61"/>
                    <measurement group_id="O2" value="49.23" spread="9.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Sheehan Disability Scale Total Score.</title>
        <description>Sheehan Disability Scale Total Score (range 0-30)measures subject's level of disability &amp; includes: work/school, social life, family life/home responsibilities, days lost &amp;days underproductive; higher scores represent higher degree of disability/impairment. Change is calculated as time point value minus baseline value.</description>
        <time_frame>Baseline (week 0), Weeks 6,12,14,16</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Sheehan Disability Scale Total Score.</title>
          <description>Sheehan Disability Scale Total Score (range 0-30)measures subject's level of disability &amp; includes: work/school, social life, family life/home responsibilities, days lost &amp;days underproductive; higher scores represent higher degree of disability/impairment. Change is calculated as time point value minus baseline value.</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 6 (n=164,165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.60" spread="7.63"/>
                    <measurement group_id="O2" value="-4.05" spread="7.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=165,166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.73" spread="7.59"/>
                    <measurement group_id="O2" value="-4.48" spread="7.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=166,166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.11" spread="7.88"/>
                    <measurement group_id="O2" value="-3.52" spread="7.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=166,166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.33" spread="8.09"/>
                    <measurement group_id="O2" value="-2.47" spread="7.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Sheehan Disability Total Scores</title>
        <description>Sheehan Disability Scale Total Score (range 0-30) measures subject's level of disability; includes work/school, social life, family life/home responsibilities, days lost, days underproductive; higher scores represent higher degree of disability/impairment. Mean values reported: baseline, double-blind(weeks 6,12)&amp; follow-up(weeks 14,16).</description>
        <time_frame>Weeks 0,6,12,14,16</time_frame>
        <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone</title>
            <description>Eszopiclone 2 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Sheehan Disability Total Scores</title>
          <description>Sheehan Disability Scale Total Score (range 0-30) measures subject's level of disability; includes work/school, social life, family life/home responsibilities, days lost, days underproductive; higher scores represent higher degree of disability/impairment. Mean values reported: baseline, double-blind(weeks 6,12)&amp; follow-up(weeks 14,16).</description>
          <population>Intention to Treat (ITT) population; Only subjects in the ITT population with at least one post-dose assessment are included. Last Observation Carried Forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (n=192,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.38" spread="7.80"/>
                    <measurement group_id="O2" value="11.13" spread="7.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=165,168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.87" spread="6.82"/>
                    <measurement group_id="O2" value="7.52" spread="6.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=166,169)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.70" spread="6.48"/>
                    <measurement group_id="O2" value="7.08" spread="6.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=166,166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.37" spread="7.21"/>
                    <measurement group_id="O2" value="8.03" spread="7.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=167,169)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.12" spread="7.10"/>
                    <measurement group_id="O2" value="9.06" spread="7.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo tablets</description>
        </group>
        <group group_id="E2">
          <title>Eszopiclone</title>
          <description>Eszopiclone 2 mg tablets</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2"/>
                <counts group_id="E2" subjects_affected="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Appendicitis Perforated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed Suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Stress Urinary Incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="61"/>
                <counts group_id="E2" subjects_affected="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MeDRA 10.1">Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title vocab="MedDRA10.1">Stomach Discomfort</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="194"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title vocab="MedDRA10.1">Dry Mouth</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="194"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title vocab="MedDRA10.1">Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="194"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA10.1">Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="194"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title vocab="MedDRA10.1">Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="194"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA10.1">Nasopharyngitis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="194"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="194"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="194"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="194"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="194"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="45" subjects_affected="24" subjects_at_risk="194"/>
                <counts group_id="E2" events="51" subjects_affected="27" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="194"/>
                <counts group_id="E2" events="35" subjects_affected="24" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="194"/>
                <counts group_id="E2" events="16" subjects_affected="8" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="194"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="194"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="194"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="194"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="194"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In addition to the &lt;60-180 day restriction above, since this is a multicenter study, 1st publication of study results shall be made with other participating study sites as a multicenter publication; if a multicenter publication is not forthcoming within 24 months following completion of study at all sites, the PI shall be free to publish.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The data gathered was subjective (except for actigraphy endpoints) and relied either on self reporting or patient assessments derived from standardized questionnaires.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Lunesta Medical Director</name_or_title>
      <organization>Sepracor Inc.</organization>
      <phone>1-866-503-6351</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

